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ABSTRACT 
JESSICA NACHEL DELBOVE:  Characterization of the Tumor Suppressor 
Capabilities of SWI/SNF Complex Member BAF155 and Cooperation of the SNF5 and 
p53 Pathways 
(Under the direction of Bernard E. Weissman, PhD) 
 
 
 Tumorigenesis is often attributed to aberrant gene expression leading to altered cell 
cycle control, abnormal differentiation, and inefficient DNA repair.  The activity of 
chromatin remodeling complexes is vital to maintaining proper control of such gene 
expression.  The SWI/SNF chromatin remodeling complex is responsible for remodeling up 
to 6% of the human genome, with many of those genes known to be associated with cell 
cycle control.  Therefore, impaired or defective activity of this complex could encourage 
tumor development.  Little is known, however, of how SWI/SNF accomplishes those tasks 
and the differing roles of the distinct members of the complex.  Composed of more than ten 
members, several components are now known to have tumor suppressive roles, as their 
absence correlates with tumorigenic phenotypes.   We propose also that core SWI/SNF 
member, BAF155, is also likely to be involved in controlling tumor progression.   I have 
utilized two carcinoma cell lines lacking endogenous BAF155 expression to explore the role 
of BAF155 in cell cycle control and found that re-expression of BAF155 in these cells leads 
to a reduction in cell number due to replicative senescence.  These BAF155 null cells were 
also found to be sensitive to Rb-mediated cell cycle arrest.  This data imply a role for 
SWI/SNF member BAF155 in cell cycle control and in turn, tumor progression.  To 
 ii
determine the pathways in which SWI/SNF core member SNF5 suppresses tumor 
progression we utilized mouse models to explore the relationship between the p53 pathway 
and that of SNF5/INI1 in controlling tumor progression and found that while double 
heterozygous mice still develop p53 wild type SNF5 null rhabdoid tumors similar to their 
SNF5+/- littermates,  SNF5 loss of heterozygosity is accelerated on a p53+/- background 
leading to reduced latency and increased penetrance of p53 null SNF5 null rhabdoid tumors 
in alternate anatomical locations as well as the formation of lymphomas.  The resulting 
rhabdoid tumors were found to express a pattern of markers similar to the human rhabdoid 
phenotype, solidifying this model as an appropriate recapitulation of human rhabdoid tumors.  
These studies shed light on the specific roles of SWI/SNF chromatin remodeling complex in 
tumor suppression. 
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CHAPTER 1 
I. Introduction 
 As patterns of genetic aberrations became evident in various neoplasms, cancer came 
to be considered a genetic disease.  The more this most complex of pathologies is studied; we 
realize it is as much epigenetic as it is genetic.  Genetically, cancer is propagated in large part 
by the aberrant expression of genes involved in cell cycle control.  Behind the scenes 
however, the decision of when, where, and if these genes are expressed is determined by 
epigenetic factors.  Chromatin remodeling complexes, like epigenetic mechanisms, operate 
behind the scenes responding to the epigenetic signals that coordinate appropriate gene 
expression patterns from development to death and every cell division in between. One of the 
best characterized chromatin remodeling complexes is the SWI/SNF complex.  Although 
affecting only a small percentage of the genome, SWI/SNF is involved in remodeling the 
chromatin of cancer.      
 
A. Epigenetic control of gene expression    
 The primary sequence of a gene is critical to determining its fate, but this one-
dimensional view is only part of what determines a gene’s physiological function.  The 
initiation and timing of a gene’s expression is often determined epigenetically.  Epigenetics 
refers to any change in gene function that occurs in the absence of a change in DNA 
sequence.  Although reversible, epigenetic changes are often stable through cell division 
(Laird, 2005).  Epigenetic changes involve the regulation of chromatin structure and DNA 
accessibility and can therefore, have a defining role in controlling gene transcription.   There 
are two main categories of epigenetic change: DNA methylation and histone modification 
(which includes acetylation, phosphorylation, ubiquitylation, sumoylation, ADP ribosylation, 
deiminatin, proline isomerization, as well as histone substitution).  DNA methylation is the 
heritable methylation of cystosine residues of CpG dinucleotides and correlates with 
transcriptional repression (Bestor, 1998).   DNA methylation is essential for survival and 
normal development (Lie, 1992, Okano, 1999, Jackson-Grusby,2001) as well as having a role 
in a variety of cellular processes from genomic imprinting, to X chromosome inactivation, 
tissue-specific gene expression, cell differentiation, and aging.    
 Histone modification also has profound effects on gene expression patterns.  By 
disrupting chromatin contacts or affecting the recruitment of nonhistone proteins to 
chromatin, these modifications orchestrate the ordered recruitment of enzyme complexes to 
manipulate DNA.  Mechanistically, histone modification is the alteration of the N-terminal 
tails of histones leading to a perturbation of the affinity between the histones and DNA.  The 
process can be covalent or non covalent.   Covalent modifications such as acetylation, 
methylation, and phosphorylation may be able to directly alter the physical properties of the 
chromatin fiber, leading to a cascade of effects on higher-order structures.  Acetylation 
specifically neutralizes the basic charge of the lysine, which may lead directly to an 
unfolding of chromatin. The repressive state of chromatin structure is usually associated with 
hypoacetylation and hypomethylation of particular residues, and the permissive configuration 
with localized phospho-hyperacetlyation and localized hypermethylation.  It is the job of 
histone modifying enzymes, as part of a larger system of transcription control involving 
chromatin remodeling complexes, to read this ‘histone code’ and unlock the chromatin, 
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exposing target genes.  Precision is necessary in the targeting of chromatin for expression of 
a specific gene, especially those involved in cell cycle regulation.  The area of chromatin 
must be found, opened, and transcribed within seconds.  It is the epigenetic histone code that 
allows for speed and precision.   
 Chromatin remodeling complexes are targeted or drawn to areas of chromatin 
according to this histone code of acetylation and methylation.  If a gene is aberrantly targeted 
or repressed, aberrant expression patterns will follow.  Such an error could occur due to 
aberrant methylation or acetylation patterns- the histone code itself.  The most common error 
of this type is aberrant transcriptional silencing of genes associated with DNA 
hypermethylation of promoter region CpG islands.  An example of DNA hypermethylation 
of a gene leading to tumorigenesis is p16 INK4A.   Hypermethylation of the p16INK4A promoter 
leads to a loss of function and is observed during progression of tumors such as lung cancer 
as early as preneoplastic lesions (Belinsky, 1998 & 2004; Nuovo, 1999).  The effects of an 
epigenetic error in this one gene are catastrophic for the cell and ultimately the individual.  
The loss of p16INK4A function allows the emergence of genomic instability (Foster, 1998; 
Kiyono, 1998) and may also directly allow for additional epigenetic silencing of other genes 
(Reynolds, 2006) causing a snowball effect to rapid tumorigenesis.  Alternatively, due to the 
histone code itself being in error, a gene could be aberrantly transcribed or repressed due to a 
misreading of the code or lack of follow through, if all complexes and required agents were 
not properly recruited to a target gene.  For example, this could mean aberrant targeting by 
transcription factors or lack of proper chromatin remodeling by chromatin remodeling 
complexes. 
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      The above scenario illustrates the intimate connection between the various epigenetic 
mechanisms, chromatin remodeling and cancer, the details of which are beginning to be 
outlined.  For example, the nucleosomal remodeling complex NuRD interacts with DNA 
methylation binding protein (MBD2) to direct the complex to methylate DNA (Zhang, 1999).  
The catalytic subunits of the chromatin remodeling complex SWI/SNF, BRG1 and BRM, are 
able to interact with acetylated histones via their bromo domains (Dhalluin, 1999; Hudson, 
2000).  SWI/SNF member BRM was also shown to associate with the methylated DNA 
binding protein MeCP2, culminating in gene silencing (Harikrishnan, 2005).   It is becoming 
increasing clear the interrelatedness of the epigenetic, chromatin remodeling, and gene 
transcription fields are to one another and to the development and progression of cancer.  Our 
study concentrates on the tumor suppressive activities of the chromatin remodeling arm of 
gene expression control, via the SWI/SNF chromatin remodeling complex.  
 
B. The human SWI/SNF chromatin remodeling complex.  
 There are several classes of ATPase chromatin remodeling complexes, but SWI/SNF is 
the quintessential ATP-dependent nucleosomes remodeling complex, initially linked to 
chromatin structure through the isolation of mutations in histone-encoding genes by Kingston 
in 1996 and Perez-Martin in 1998.  These original experiments into the yeast function and 
specific dysfunctions, lead to their discovery and name: mating type SWItching and Sucrose- 
Non-Fermenting to yield SWI/SNF (Winston, 1992).   In 1999, Kingston and co-workers 
further showed that the ATP-dependent action of SWI/SNF causes the disruption of 
nucleosome structure, leading them to propose the current model of SWI/SNF action- in vivo 
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Figure 1-1 
 
 
Schematic of chromatin remodeling by the SWI/SNF chromatin remodeling complex by 
octomer transfer or octamer sliding.  
 
Image adapted from: Roberts, C. and S. H. Orkin (2004). "The SWI/SNF Complex- 
Chromatin and Cancer." Nature Reviews Cancer 4: 132-142. 
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disruption of chromatin structure at promoters to facilitate the binding of transcription 
factors.  The complex accomplishes this task by physically altering the nucleosomes 
structure, displacing it to expose target DNA. 
 SWI/SNF is now established as being evolutionarily conserved from yeast to man, 
where it maintains a constant core of BRG1 or BRM (Brahma), with SNF5/INI1, and 
BAF155/170, as well as several other variable members to make a 2 megadalton, 8-12 
member complexes.  The inclusion of specific non-core members is tissue- and 
developmental stage-specific (Wang, 1996).  Loss of any member leads to nearly identical 
phenotypes in yeast, likely due to a requirement of all members to have a fully functional 
complex (Winston, 1992, Kingston 1999).  Further yeast studies revealed, via microarray, 
that the complex is involved in the transcriptional regulation of up to 5% of genes 
interspersed throughout the genome, repressing more than activating (Sudarsanam, 2000).  It 
is believed that the unique, variable SWI/SNF subunits are involved in targeting and 
structural functions of the complex, while the core is responsible for the actual remodeling.  
For example, the actin-like subunit BAF53 is likely involved with anchoring the complex to 
the nuclear matrix. In mammalian cells several variants of the complex exist: SWI/SNF-A 
(BAF), SWI/SNF-B (PBAF), and E-BAF complexes (see Figure 1-2).  
 These complexes are similar but have distinct components and regulate mutually 
exclusive target genes (Wang 2003).  These unique functions may be due to the distinct 
members in the differing complexes.  Structural domains involved in protein-protein 
interactions are present in BAF250a/ARID1A/p270 and BAF250b/ARID1B, BAF180, 
BAF170, BAF155, BAF60, BAF53, and BAF47SNF5/INI1.  Various different sequence-
dependent and sequence-independent DNA binding domains can be found in BAF250, 
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BAF180, BAF170, BAF155, and BAF57.  We know BAF57, only found in higher 
eukaryotes, is a critical modulator of the androgen receptor –whose activity is required for 
prostate development, growth, and survival (Link, 2005).  Nagl et al has demonstrated the 
necessity of BAF250 in specific proliferation control steps, the loss of which leads to 
carcinogenesis.  BAF60c has been demonstrated to be essential in the developing heart in 
mice (Lickert, 2004).   
 Although variation among complexes leads to specificity and variable phenotypic 
disorders upon loss or mutation of specific complex members, the theme of dysfunction 
remains a lack of proper chromatin remodeling, which is ultimately the responsibility of the 
SWI/SNF core.  There is variation in the multiple SWI/SNF complexes among the non-core 
as well as core members, although it is always a combination of BRG1 (or BRM) with 
SNF5/INI1 and BAF155/BAF170.   BRG1 and BRM are the larger of the core members and 
contain the ATPase domains to fuel the remodeling.   SNF5, on the other hand, is the 
smallest of all SWI/SNF members and is an established tumor suppressor gene connected 
with human rhabdoid tumors.  BAF155 and BAF170 have high sequence homology and do 
not yet have distinct identified roles in the complex.  As mentioned previously, these subunits 
form a chromatin remodeling complex involved in remodeling 5% of the genome.  This is a 
small but very important 5% as many of the genes affected by the SWI/SNF remodeling are 
cell cycle related.  Proper cell cycle regulation touches nearly every important moment in the 
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Figure 1-2: 
 
Schematic of the various mammalian SWI/SNF complexes.  The complexes differ by 
catalytic subunit either BRG1 or BRM, accompanied by varying smaller subunits.  Precise 
combinations depend on cell type, developmental stage, and other micro-environmental 
effectors. 
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 life of a cell: development, differentiation, replication, repair, age-related senescence, and 
apoptosis.   The following segments will outline specific functions correlated with SWI/SNF 
activity. 
 
1. SWI/SNF in normal cellular processes: Development and aging 
  The coordination of precise cell division or death signals, proper growth and 
differentiation during development, as well as normal growth and aging are understandably 
dependent on proper epigenetic control. It is known that changes in gene expression during 
embryonic development are accompanied by reorganization of the chromatin.  There are 
several lines of evidence implying this reorganization is one of the roles of the SWI/SNF 
complex.  The fundamental function of a chromatin remodeling complex is to remodel 
nucleosomes, so it is logical that the consequences would be dire upon loss of function of a 
core member. This is indeed the case, as loss of any core member in mice is not compatible 
with life, demonstrating the importance of the SWI/SNF complex to development.  Given the 
role of these genes as part of an epigenetic complex, it is not surprising that large-scale 
aberrant gene expression leading to death results with their loss.  The majority of what is 
known of SWI/SNF’s role in development concerns these core members.  Although the 
strongest evidence for SWI/SNF’s role in development does stem from the core members, 
there are studies showing roles for various other subunits of the complex; BAF57 in 
androgen-dependent proliferation (Link 2005), BAF60c in heart development (Lickert, 
2004), BAF180 in cardiac chamber maturation (Wang 2004), and BAF200 in regulation of 
expression of selective interferon-responsive genes (Yan, 2005).  The following will outline 
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correlations between SWI/SNF core members and the development and differentiation of 
neural and lymph tissue.   
  While homozygous loss of any core member is embryonic lethal, a subset of the 
heterozygotes develop neural tube defects manifesting as exencephaly (Bultman, 2000; Kim, 
2001; Roberts, 2000).  BRG1 has surfaced as having several vital roles in the development of 
this and multiple other tissue types.  Seo demonstrated in 2005 that BRG1 is specifically  
required for cell cycle exit and neuronal differentiation of neural progenitor cells.  Loss of 
BRG1 expression has been shown in vitro to abrogate MKK6-dependent induction of muscle 
gene expression (Simone, 2004)   And a lack of BRG1 in developing T cells leads to a 
complete lack of CD8 and CD4 positive T cells, as well as leading to a Bcl-2 induced 
apoptosis (Chi, 2003).  Double positive T cell apoptosis is also linked to expression levels of 
a second core member, BAF155.  Although each core member will be detailed more 
extensively later, briefly: Srg3 (mouse BAF155) is expressed at higher levels in the thymus 
than other surrounding developing tissues, where it is involved in T-cell apoptosis 
susceptibility.  Sensitivity to glucocorticoids in T cells can be modified by altering the 
expression levels of Srg3. As outlined further in the section on BAF155 below, it also 
appears to have an important role in the inhibition pathway of glucocorticoid-mediated 
apoptosis by T-cell antigen receptor (TCR) (Ko, 2004).  SNF5 has been implicated in the 
survival of hematopoietic cells as well, from mouse studies where SNF5 loss coincides with 
bruising and intestinal hemorrhage so severe it leads to the death of these mice (Roberts, 
2002).   
 In keeping with a similar theme of SWI/SNF involvement in cellular processes 
involving growth control and development, so too is that SWI/SNF is involved in aging, at 
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least in the form of cellular senescence.  If any of the three main core members BRG1, SNF5, 
or BAF155 are re-introduced into cell lines lacking endogenous expression, senescence is 
observed, demonstrated by growth arrest, expression of senescence marker β-galactosidase, 
and often a flat cell morphology can also be observed (Dunaief, 1994; Hendricks, 2004; 
Kang, 2004; Shanahan, 1999).  Studies done by Yaniv and colleagues as well as the Roberts 
lab have reinforced this role for SNF5 by showing SNF5 can produce replicative senescence 
in mouse embryonic fibroblasts (MEFs) in culture upon loss of SNF5 (Roberts, 2002; 
Klochendler-Yeivin, 2006).  While core member BRG1 was shown to be essential to the 
proper differentiation of specific tissues, its counterpart, BRM, seems to be associated with 
the scheduled aging of specific tissues.  The normal regenerative capacity of the liver is lost 
in older mice coinciding with the arrival of an apparent repressive complex involving BRM 
(Iakova, 2003).   Several of the above mentioned and other developmental, differentiation, 
cell cycle interactions can be seen schematically in Figure 1-3.  
 
2. Involvement of SWI/SNF in cell cycle control pathways:   
 An obvious link exists between development, aging, and cancer.  All are intimately 
associated with precise and coordinated cell cycle control, albeit in a pathologic way with 
cancer.  Although SWI/SNF does not directly control the cell cycle, there is great 
circumstantial evidence the complex is involved with the transcriptional regulation of several 
entities that do play key roles in cell cycle progression.  The clearest of these links is with the 
Rb pathway.   
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Figure 1-3: 
 
Example of the many pathways that target the mammalian SWI/SNF complex. 
 
Adapted from:   Simone, C. (2006). "SWI/SNF: The Crossroads Where Extracellular 
Signaling Pathways Meet Chromatin." Journal of Cellular Physiology 207: 309-314. 
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 a) The Rb pathway.  
 The retinoblastoma protein, pRb, is one of the major regulators of the cell cycle.   It is 
responsible for controlling the G1/S transition and progression through S phase.  In its 
hypophosphorylated state, Rb associates in early G1 with the E2F transcription factors to 
recruit HDACs, causing the repression of Cyclins A and E involved in cell cycle progression.  
Subsequently in late G1, phosphorylation of the Rb pocket results from accumulated Cyclin 
D/Cdk4/6 complexes, which in turn leads to the displacement of the HDAC activities and 
eventually to release and activation of E2F, and cell cycle progression. 
 
b) SWI/SNF and the Rb pathway 
  Several studies have demonstrated a need for components of the SWI/SNF 
remodeling complex for the proper functioning of the Rb pathway.  A physical interaction 
between Rb and SWI/SNF was originally discovered in a yeast two-hybrid screen using Rb 
as bait which demonstrated an interaction between Rb and BRG1 or BRM (Dunaief, 1994).   
The Zhao lab further demonstrated an interaction between BRG1 and Rb by showing that 
BRG1 can upregulate p21.  This induced the hypophosphorylation of pRb, activating pRb 
(Kang, 2004).  Since then, more functional assays have implicated a necessity for 
BRG1/BRM in the control exerted by pRb on the G1/S transition.  The Goff lab has 
demonstrated a functional requirement for BRM or BRG1 for Rb induction of growth arrest 
(Dunaief, 1994; Strober, 1996), corroborated by several others groups (Zhang, 2000; 
Dunaief, 1994; Reisman 2002; Strobeck, 2000a and 2002; Trouche, 1997). One example, 
seen in SW13 cells which lack BRG1 and BRM, where growth arrest is not induced upon 
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exposure to a constitutively active hypophosphorylated Rb unless BRG1 or BRM are also 
expressed (Strobeck, 2000a,b).  The physical interaction between BRG1/Brm and Rb family 
members was further demonstrated by Strober (1996) and Trouche (1997) with both BRG1 
and BRM able to bind p107 and p130.   Zhang et al (2000) further showed a requirement for 
SWI/SNF in the coordinated expression of Cyclin E and A during late G1 and S phases via 
BRG1’s association with Rb.   This finding was supported by the observation that cells 
growth-arrested by BRG1 and pRb accumulated in S phase and not G1.  Cyclin E has been 
linked to SWI/SNF via an Rb-independent interaction with phosphorylated BRG1 and 
BAF155 (Shanahan 1999), as discussed in further detail in the section on BAF155.  Some of 
the key points in the relationship of Rb, SWI/SNF, and the cell cycle are diagramed below in 
Figure 1-4. 
 
c) The p53 pathway 
 The statistic usually quoted to show the significance of p53 loss in human cancer 
development is that it is lost, mutated, or otherwise inactivated in most human cancers.  
While this is indeed the case, it is the fact that the p53 pathway has failed in its response to 
successfully halt the cell cycle due to DNA damage that underlies its role in human cancer.  
Cells are routinely exposed to DNA damaging agents, some endogenous, by the induction of 
mismatches, crosslinks or strand breaks.  DNA damage of one sort or the other is often the 
first step to genomic instability, which has also been considered a hallmark of human 
neoplasms.  Without functioning guardians of the genome like p53, such DNA 
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Figure 1-4 
 
Schematic depicting the relationship between the SWI/SNF complex, RB, and cell cycle 
control.   
 
Adapted from:   Roberts, C. and S. H. Orkin (2004). "The SWI/SNF Complex-Chromatin and 
Cancer." Nature Reviews Cancer 4: 132-142. 
 18
  
 
 
 
 
 
 
 
 
 
  
HDAC
P
SWI/SNF
SWI/SNF
P
Cyclin E 
CDK2 
CDK4 
RB
RB
Cyclin E
Cyclin D 
Cyclin E
SWI/SNFRB
Cyclin A
PP
Cyclin A
M
G2
S
G1
CELL 
CYCLE 
Cyclin A
 
 
 
 
Figure 1-4 
 19
damage or instability leads to aberrant gene expression of oncogenes or loss of expression 
tumor suppressors.  If not repaired correctly, these lesions can be particularly mutagenic.  
Double strand breaks, for example, can recombine inappropriately driving gross 
chromosomal instability.  The appropriate response of a cell to such damage is to attempt to 
repair or undergo apoptosis.  Apoptosis is not always due to catastrophe, it is also signaled as 
part of normal development in some structures, or to protect the organism from self-reacting 
immune cells.   As an adult, one of the most important roles of apoptosis is in removing cells 
with compromised genetic integrity on the road to malignant transformation.    
 The agent often employed in carrying out the choice of cell suicide is the p53 tumor 
suppressor protein (Vousden, 2002).  Once stabilized, the p53 protein may induce apoptosis 
if the damage is deemed irreparable.  However, at times where the cell may effectively repair 
the injuries, the appropriate response may be cell cycle arrest.   The arrest can allow the cell a 
pause to temporarily or permanently prevent the perpetuation of the recognized genetic 
damage in a cell, be it DNA damage repair defects, hypoxia, or aberrant proliferative signals.  
The decision to arrest or apoptose is not fully defined but seems to depend largely on cell 
type and environment (Vousden, 2000; Vogelstein, 2000; Levine, 1997; Hansen, 1997; 
Bates, 1996).  It is this loss of a functional checkpoint that facilitates genetically unstable 
cells to propagate and continue on to malignant transformation, not the loss of p53 directly, 
per se. As mentioned previously, upon DNA damage, p53 becomes stabilized and 
accumulates in the nucleus.  The build up may, according the cell type and stimuli, up 
regulate p21, which will in turn halt the phosphorylation of pRb by cdk2/cyclinE.  This will 
leave pRb in the hypophosphorylated state, not allowing the progression of the cell cycle.   
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Figure 1-5: The p53 signaling pathway.   
 
Adapted from images on the Sigma-Aldrich website:  
http://www.sigmaaldrich.com/Area_of_Interest/Life_Science/Cell_Signaling/Scientific_Reso
urces/Pathway_Slides___Charts/The_p53_Signaling_Pathway.html   
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Alternatively, the increase in p53 in the nucleus could lead to Bax induction of the caspase 
cascade leading to apoptosis.  These, and other specific pathways involved, can be seen 
schematically in Figure 1-5. 
 
d) SWI/SNF and the p53 pathway   
 The exact mechanisms by which SWI/SNF affects cell cycle control is not 
understood.  However abundant evidence leaves no doubt unfettered cell growth may result 
without fully functional SWI/SNF.   Regulation or even association with key cell cycle 
‘gatekeepers’ such as p53 may be the key.  Lee et al demonstrated in 2002 through ChIP 
analysis that hSNF5 and BRG1 are recruited to the p53-dependent promoter, p21 and directly 
activate p21 expression.  Overexpression of either SNF5 or BRG1 in a dominant negative 
form inhibited p53-mediated cell growth suppression and apoptosis.  Furthermore, binding of 
BRG1 to BRCA1, as shown by Bochar et al in 2000, is required for BRCA1 stimulation of 
p53-dependent transcription.  The SWI/SNF complex likely has the severe effects on 
development and cancer due to the aberrant chromatin remodeling of at least one gene 
important to cell cycle control.  The p53 tumor suppressor gene is just such a gene.  Our 
studies were designed to shed light on the potential role of the SWI/SNF complex on p53 
tumor suppression in vivo. 
 
3. Involvement of SWI/SNF in cancer.    
 The role of SWI/SNF in cancer appears certain, if not well defined.  A complex so 
intertwined in the fabric of epigenetic control of cell cycle regulatory genes is also 
inseparable from tumorigenesis.  Several SWI/SNF complex members are required for proper 
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functioning of important cell cycle control processes in development, aging, and normally 
growing cells as outlined above.  It is inevitable that patterns surface between lost or 
malfunctioning complex members and human neoplasms.  This is the case with SWI/SNF 
core members BRG1 and SNF5.   More detail will be given in following sections of SNF5 
but a brief description of SNF5 and BRG1 in cancer follows.  SNF5 is the first SWI/SNF 
complex member to be dubbed a bona fide tumor suppressor gene, being the distinguishing 
characteristic in the diagnosis of malignant rhabdoid tumors (MRTs).  SNF5 loss is found in 
a majority human MRTs whether due to germline or sporadic etiology (Biegel, 2002; 
MacDonald 2003; Reddy, 2005).  While it seems SNF5 has a role in development as well as 
pediatric tumors, loss of BRG1 seems to affect adult tumorigenesis.  Although loss of BRG1 
in primary tumors is not widespread, it has been noted in several lung cancer cell lines as 
well as some oral cancers (Reisman, 2003; Gunduz, 2005).  Approximately ten percent of 
human cancer cell lines screen display a mutation or complete loss of BRG1, including 
pancreatic, breast, lung, and prostate cancer cell lines (DeCristofaro, 2001; Wong, 2000).  
Loss of both BRG1 and BRM is found in approximately 30% of human non-small cell lung 
cancer cell lines and 10% of primary tumors.  The lack of BRG1 or BRM seems to correlate 
with a poor prognosis in these patients (Reisman, 2003).  Loss of these members may not 
even be necessary to lose function, aberrant BRM cellular localization has correlated with 
poor prognosis in lung adenocarcinoma patients (Fukuoka, 2004).  This strong link is 
furthered by the appearance of breast adenocarcinoma-like glandular tumors in BRG1 
heterozygote mice (Bultman, 2000).  BRM heterozygotes do not readily form tumors but 
display the phenotypic symptom of being generally larger in size, compared to wild type 
littermates (Reyes, 1998).  Less is known of the third core member, BAF155.  It is found in 
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an area of chromosome 3 (3p) that has been reported lost in primary carcinomas.  While 
widespread loss of BAF155 expression in primary tumors has not been reported, we have 
found 2 carcinoma cell lines lacking BAF155 expression.  Core members SNF5 and BAF155 
are the focus of my dissertation studies and are discussed in more depth below. 
 
C. The SNF5 tumor suppressor gene 
 Cancer has a very well defined, even primary, genetic component, but as we are 
beginning to see, epigenetics plays perhaps as important a role in cancer development and 
progression.  SNF5 loss combines the genetic and epigenetic fields in the understanding of 
the mutual importance of these two in controlling cell cycle progression and tumorigenesis.  
The majority of MRTs have lost the SNF5 allele, but otherwise typically have a completely 
normal karyotype (Douglass, 1990).  The aggressive nature of these tumors may be explained 
by extensive ‘epigenetic instability’.   
 SNF5 appears important for the SWI/SNF complex for its control of the cell cycle, 
via p16 and p21 transcriptional regulation (Chai, 2005).  SNF5 first came to be considered 
involved in human cancer progression with the discovery of loss of heterozygosity of the area 
of chromosome 22 where SNF5 maps (22q11.2) (Biegel, 1990 & 1996; Rosty, 1998).   SNF5 
was later found to be lost in the majority of human rhabdoid tumors (Versteege, 1998).  The 
discovery of SNF5 as an important molecule in association with devastating disease 
processes was not limited to cancer.  SNF5’s INI1 designation came from its involvement in 
HIV integration (Kalpana, 1994).  For association with other SWI/SNF subunits it was also 
called BAF47 (BRG1-associated factor of 47 kD) by Wang et al.   Also known as 
SMARCB1, it will be referred to as SNF5 throughout this document.  The smallest of the 
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SWI/SNF subunits, the human protein contains three conserved domains: two repeats (repeat 
1 and repeat 2) and a C-terminal coiled-coil domain.  There is near 100% conservation of 
SNF5 from mouse to man, although the human SNF5 protein exists as two splice forms, one 
containing a lysine rich domain not present in the short isoform (SNF5-sp).  The first repeat 
domain has been show to be critical for the interaction of SNF5 with several factors: BRM, 
c-MYC, HPV-E1, and HIV-IN (Muchardt, 1995; Lee, 1999; Cheng, 1999).  Repeat 2 is 
required for SNF5 interaction with BRM and GADD34 (Wu, 2002), and possibly as a 
nuclear export signal (NES). The coiled-coil domain has an unusual anti-export signal 
(Cosma, 1999).  It is most often the repeat domains that are lost in human cancer patients 
(Biegel 1999 & 2000; DeCristofaro, 1999; Savla, 2000; Sevenet, 1999a, b; Versteege, 1998).   
 
1. The role of SNF5 in development.  
 As outlined earlier, the complex as a whole has a role in development as well as 
cancer, and this holds true for the SNF5 subunit as well.  SNF5’s links to development have 
revealed themselves in neural and hematopoietic development.  As mentioned earlier, 
complete loss of SWI/SNF core members BRG1, BAF155, or SNF5 results in embryonic 
lethality – so an obvious role in development is implied.  A subset of heterozygotes of these 
studies all display neural tube defects.  In the case of SNF5, the tube defects may be due to 
the observed deficiency of RHO activity essential for neural crest cell delamination from the 
dorsal neural tube (Medjkane, 2004; Liu, 2001; Edelman, 1998).  The hematopoietic 
necessity of SNF5 is best demonstrated in mouse studies of conditionally null mice or 
tissues.  Loss of SNF5 expression in hematopoietic cells in the bone marrow of these mice 
leads to their death in a rapid fashion (Roberts, 2002).  The same study showed a less 
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penetrant conditional SNF5 mutation that affected approximately half of all tissues (except 
brain) and left these mice predisposed to CD8+ T cell lymphomas.  
 
2. The role of SNF5 in tumor formation.   
 Pediatric neoplasms have always been emotionally devastating cancers and in the 
case of rhabdoid tumors, even more so, as these tumors are particularly aggressive, killing 
over 80% of affected children with a median age of onset of 11 months.  Recognized as such, 
as early as 1978, it was described as a unique sarcomatous variant of Wilm’s tumor with very 
aggressive clinical behavior (Beckwith, 1978).  The same group later identified the kidney 
tumors as distinct and dubbed them ‘malignant rhabdoid tumor of the kidney’ due to its 
morphological resemblance to rhabdomyoblasts, but with a lack of ultrastructural evidence 
for skeletal muscle differentiation (Haas, 1981).  Extrarenal rhabdoid tumors are now 
recognized as typical as well, in as diverse locations as the liver, chest wall, and CNS 
(Gonzalez-Crussi, 1982; Lunch, 1983; Tsuneyoshi, 1985).  These tumors have always 
presented a diagnostic challenge given the largely undifferentiated although heterogeneous 
appearance, polyphenotypic immunoprofiles, and similarities to similar tumor types.  The 
designation of rhabdoid has relied on the histological appearance of large epithelioid cells 
with eccentric eosinophilic cytoplasm, vesicular nuclei, prominent nucleoli, and whorled 
bundles of keratin positive intermediate filaments.  False diagnoses were frequent, leading to 
unsuccessful treatments.  The discovery of deletions and mutations at 22q11.2 involving 
SNF5/INI1 has since facilitated diagnosis and treatment choices (Versteege, 1998; Biegel, 
1999; Sevenet 1999a&b; Rousseau-Merck, 1999).  The genetic mutation in MRTs is usually 
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specific to SNF5, not chromosome or genome wide losses or instability, implying it is the 
specific loss of SNF5 that allows these tumors to form.    
 If there was any question of the causal relationship of SNF5 loss and rhabdoid 
formation, that was put to rest by several groups showing a predisposition to the formation of 
rhabdoid tumors in Snf5+/- mice, up to 30% penetrance by 15 months (Roberts, 2000; 
Klochendler-Yeivin, 2000, Guidi, 2001).  As mentioned above, while nullizygotes were 
embryonic lethal, dying at the peri-implantation stage, conditional SNF5 null mutants lead to 
death within 3 weeks of SNF5 loss due to hematopoietic failure.  A reversible conditional 
mutant that causes only partial penetrance of loss was able to avoid the bone marrow failure 
and death experienced with the fully penetrant conditional mutation.  These mice also 
experienced a fully penetrant phenotype, developing CD8+ T cell lymphomas or rhabdoid 
tumors by 11 weeks (Roberts, 2002).  The 100% penetrance observed by 11 weeks of SNF5 
loss brings SNF5 to the top of the list of deadly genetic mutations in cancer, as studied in 
mice.  Loss of either tumor suppressor gene p53, or p16INK4A leads to tumor development at 
median ages of 20 weeks and 38 weeks, respectively (Sharples, 2001; Donehower, 1992).  
 Attention then turned to how SNF5 suppresses tumor formation, i.e. what pathways 
were involved.  It had been established that BRG1 and BRM both bind RB and cooperate in 
RB-mediated growth suppression and repressor activity (Dunaief, 1994; Reisman, 2002; 
Strobeck, 2000b; Strober, 1996; Trouche, 1997; Zhang, 2000).  With the knowledge that RB 
is one of the most commonly lost tumor suppressor genes in human cancer, and the fact that 
it was not known whether inactivation of SNF5 in tumors disrupts Rb function, it was 
questioned if SNF5 functioned through the Rb pathway.  Exploring the SNF5-Rb pathway 
connection, Tsikitis et al has recently shown that cyclin D1 absence allows Snf5+/- mice to 
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survive tumor free, and have also found cyclin D1 positive cells in primary mouse and 
human rhabdoid tumors, suggesting cyclin D1 is a mediator of rhabdoid tumorigenesis.  
Fujisawa, 2005 also found overexpression of cyclin D1 in several primary human rhabdoid 
tumors, but not in tumors lacking SNF5 inactivation, supporting Tsikitis et al’s findings.  
Interaction of SNF5 with c-Myc, Cyclin D1, and p21 led to the question of cooperation 
between these two tumor suppressors physiologically.  Guidi et al showed in 2006 that loss 
of the Rb pathway is epistatic to loss of SNF5 in tumor formation, although the interesting 
finding of SNF5 null pituitary tumors has created questions of Rb and SNF5 interaction in 
the pituitary.  More recently, a similar cross of mice haploinsufficient for SNF5 as well as 
losing the pRb family via a cross with TgT121 mice (a truncated SV40 large T antigen that 
inactivates pRb and family members 107, and p130) revealed cooperation between SNF5 and 
the Rb family in tumor suppression as loss of both significantly accelerates MRT formation 
(Chai, 2007).   Although every step involved in the SNF5 pathway to tumor suppression is 
not yet known, it seems fairly certain the Rb pathway is manipulated.   
 Given the paradoxical role of SNF5 as tumor suppressor and cell survival gatekeeper, 
it is important to determine if other known cancer signaling pathways are involved.  Aberrant 
proliferation can lead to Rb inactivation and subsequent apoptosis.  As discussed above, the 
p53 signaling pathway plays a major role in regulating apoptosis (Debbas, 1993; Lowe, 
1994; Macleod, 1996; Morgenbesser, 1994; Howes, 1994; Sabbatini, 1995; Wagner, 1994).   
Logically, the aberrant proliferation creates a selective pressure to lose p53 for tumor 
survival and proliferation.  This has actually been demonstrated by Symonds et al where 
epithelial cell tumorigenesis occurs in response to pRb pathway inactivation, where normally 
Rb inactivation of the choroid plexus epithelium would result in p53-dependent apoptosis 
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(Lu, 2001).  In fact, it is well documented that most human tumors harbor inactivation of 
both Rb and p53 (Weinberg, 1995).  It was this suspicion that has lead Roberts and co-
workers and Yaniv and colleagues to investigate the interaction of SNF5 and p53 tumor 
suppressors in rhabdoid tumorigenesis.  Klochendler-Yeivin et al (2006) demonstrated p53 
nullizygosity indeed accelerated rhabdoid tumor formation in SNF5 heterozygous mice – 
with complete penetrance within 19 weeks (from 28 weeks on wild type p53 background).  
Neither the tumor spectrum, nor anatomical locations of the resultant rhabdoid tumors, were 
altered.   Although the above mentioned study, like the SNF5 null mutant mouse studies, are 
extreme and less likely to represent a true physiologic state, they do support the theory put 
forth earlier that p53 inactivation allows the SNF5 null cells to progress unfettered to 
aggressive rhabdoid tumors.   To observe a more physiologically likely and therefore more 
relevant representation of any effects of combined SNF5 and p53 loss, the study presented 
here reveals an indication of the cooperation between these two very important tumor 
suppressor pathways. 
 
3. Mechanism of SNF5 tumor suppression.   
 Once established as a classic tumor suppressor gene, attention has turned to 
determining the mode of tumor suppression of SNF5.  At least one major mode of the tumor 
suppressive abilities of SNF5 appears to be, indirectly or otherwise, through control of the 
cell cycle.   Binding to c-MYC, BRCA1, and p53 links SNF5 to multiple cell cycle control 
pathways and other tumor suppressor pathways (Hill, 2004; Lee, 2002; Bochar, 2000, Gartel, 
2003). c-MYC is involved in controlling regulation of cell growth, genomic stability, 
angiogenesis, cell transformation, differentiation, and apoptosis, and aberrant expression is 
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found in many tumor types (Amati, 2001).  c-MYC is involved in E2F pathway induction, 
specifically by nullifying the block on cyclins E and D1 by p21, which is furthered by pRb 
phosphorylation and subsequently S phase progression.  A dominant negative form of SNF5 
abrogates the transactivation function of c-Myc (Cheng, 1999).   
 The link of SNF5 to the Rb pathway continues with the fact that cells lacking SNF5 
often exhibit polyploidy in a subset of cells, that are no longer detected upon reexpression of 
SNF5 (Vries et al, 2006).  This so-called ‘ejection’ of poly- and aneuploid cells was 
accomplished by SNF5 by transcriptionally regulating members of the p16/pRb/E2F pathway 
in SNF5 null, MRT-derived cell lines, upon re-expression.   The induction of the Rb pathway 
was exemplified by the G1 arrest, cellular senescence, and apoptosis seen in MRT cell lines 
upon SNF5 re-expression (Ae, 2002; Betz, 2002; Versteege, 2002; Zhang 2002), that was 
determined to be due to direct transcriptional activation of p16INK4A (Oruetxebarria, 2004), as 
well as E2F and cyclin D1.  This was supported by work done in our lab as well, where re-
expression of SNF5 led to promoter binding of p16, p21, and increased levels of p18  in a 
rhabdoid cell line (Chai, 2005) accompanying a flat cell morphology, growth arrest and β-
galactosidase and PML expression (Betz, 2002; Versteege, 2002; Oruetxebarria, 2004).   
 When SNF5 is inactivated in primary mouse embryonic fibroblasts, immediate and 
widespread changes in ~5-10% of the genome can be observed.  Microarray analysis of 
SNF5+/+ as opposed to SNF5-/- mouse embryonic fibroblasts identified over 1200 effected 
genes, 978 repressed in SNF5 deficient MEFs and only 322 activated genes (Isakoff, 2005).  
Specifically, the SNF5 deficient MEFs showed a decrease of p16INK4A, and a ‘highly 
significant’ increase in E2F targets.  SNF5 deficient MEFs have been observed to arrest upon 
SNF5 re-expression, which may seem to contradict this apparent genetic push toward cell 
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cycle progression.  The cell cycle arrest MEFs experienced upon re-expression of SNF5 is 
accompanied by apoptosis, polyploidy, and an increase in p53, as well as a 2-3 fold increase 
in transactivational induction of p53-targets Mdm2 and Puma (a pro-apoptotic Bcl-2 family 
member) (Klochendler-Yeivin, 2006).  Therefore, it is possible that an attempt was made at 
cell cycle progression by these damaged cells, triggering the p53 apoptotic/arrest pathway.   
This was corroborated in mouse studies where both SNF5 and p53 were knocked out 
conditionally leading to tumor formation in less than one month of age compared to 11weeks 
in the conditional SNF5 null comparison.  SNF5 was still considered to be the ‘dominant’ 
phenotype in these mice however, because the tumor type seen is that of SNF5 deficient 
mice, not the tumor spectrum in the p53 knockout mice.  Again, as previously mentioned, 
because SNF5 binds to the p21 promotor when re-expressed in MRT cells (Chai, 2005) and 
the association of SNF5 and BRG1 with p53 (Lee, 2002) is lost in the absence of SNF5, it 
does not seen surprising that the aggressive MRTs grow rampant when both SNF5 and p53 
tumor suppressors are lost.  The mouse study presented here supports this theory that p53 
loss allows SNF5 deficient cells to form tumors unfettered, leading to an increase in SNF5 
null type tumors at a higher rate than that seen on a wild type p53 background.  
 
D. SWI/SNF core member BAF155  
 BAF155 first came into focus when it was identified as a gene highly expressed in the 
thymus compared to the periphery by subtractive hypbridization (Jeon, 1997).  It has since 
been found to be evolutionarily conserved and therefore, as with the other conserved 
subunits, has multiple names: Moira in Drosophila, Swi3 in yeast, Srg3 (Swi3-related gene) 
in the mouse, and BAF155 (BRG1-associated factor 155kD) in humans – and will referred to 
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as BAF155 in this document unless specifically referencing another species.  BAF155 is also 
one of the core subunits of the SWI/SNF chromatin remodeling complex.  Its precise 
function beyond that is still coming into focus.  Several clues hint at a role for BAF155 in 
maintaining the complex itself, as outlined below.  The protein itself has several highly 
conserved domains: the SANT (SWI3, ADA2, N-CoR, and TFIIIB) domain, the SWIRM 
(SWI3, RSC8, and MOIRA) domain, and the leucine-zipper motif.  A schematic diagram of 
BAF155 protein domains can be seen in Figure 1-4.  SANT domains in general tend to be 
associated with transcriptional activating proteins and was reported in the case of BAF155, to 
be important to the interaction of BAF155 with fellow SWI/SNF core member BRM in 
Drosophila (Crosby, 1999).  More recently, BRG1 was shown to interact directly with the 
SANT domain of SRG3 in mice (Sohn, 2007).  Chen et al 2005 showed that BAF155’s 
leucine zipper motif is vital to its interaction and stabilization of SWI/SNF subunit BAF57.   
The leucine zipper motif also allows BAF155 to exist as a homodimer or to heterodimerize 
with its close homolog in the complex, BAF170 (Wang, 1996b).  The SWIRM domain of 
SRG3 was shown to be responsible for the direct interaction with BAF60a, and SNF5, which 
is stabilized by this interaction (Sohn, 2007).   It is this combination of interactions that hints 
that BAF155 may be a scaffold protein whose primary function in the complex is stability.   
This implies a potential loss of function for the entire SWI/SNF complex if individual 
members cannot be stabilized due to loss of BAF155.  
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Figure 1-6:  Schematic of the protein domains of SWI/SNF core member BAF155.   
 
Image adapted from:   Chen, J. and T. Archer (2005). "Regulating SWI/SNF Subunit Levels 
via Protein-Protein Interactions and Proteasomal Degradation: BAF155 and BAF170 Limit 
Expression of BAF57." Mol Cell Biol 25(20): 9016-9027. 
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 Although no statistics are published concerning the loss of BAF155 in primary 
tumors, loss of a large area of chromosome 3 where BAF155 maps (3p21) is lost in many 
lung and other adenocarcinomas.  Several 3p deletions are detected in nearly 100% of small 
(SCLC) and greater than 90% of non-small cell lung cancers (NSCLCs) ensuring the 
presence of at least one tumor suppressor gene on the short arm of chromosome 3 
(Zabarovsky, 2002).  Other than the two carcinoma cell lines discovered in our lab that lack 
BAF155 protein expression, as described here, there are no further links of BAF155 to 
cancer.  BAF155 may resemble fellow core member BRM in this respect, with defined 
importance in development and differentiation more than in tumorigenesis.  The Seong lab 
has pioneered studies into BAF155’s role in mouse development with several papers showing 
the absolute requirement for a full complement of the SWI/SNF core members, as when 
BAF155 expression is deficient, embryonic lethality results (Kim, 2001) in the mouse (which 
makes it very different from BRM-null mice).  The BAF155 null embryos were lost soon 
after decidualization by defects in the inner cell mass (ICM) and the primitive endoderm. 
This is a similar phenotype observed with loss of other SWI/SNF core members SNF5 and 
BRG1 who experience neural tube defects resulting in embryonic lethatlity of nullzygous 
mice and exencephaly of heterozygotes, as detailed earlier.  On a cellular level, they also 
showed the need for BAF155 for proper development of T-cells, as with BRG1. 
 Clonal deletion of immature T cells, which are nonfunctional or self-reactive, is 
crucial for maintenance of the normal immune system.  Glucocorticoids (GCs) have been 
suggested to trigger this apoptosis of T cells and eliminate developing thymocytes failing to 
differentiate properly (Vacchio, 1999; Ashwell, 2000; Pazirandeh, 2002).  Loss of Srg3 
expression in thymomas decreases the apoptosis induced by glucocorticoids (GCs), 
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suggesting the necessity of BAF155 in the GC-induced apoptosis during T-cell development 
(Kim, 2001).  It was further found that the sensitivity afforded developing T cells to GC-
induced apoptosis by SNF5 is inhibited by down regulation of Srg3 by T-cell antigen 
receptor (TCR) signaling (Ko, 2004).  This TCR repression of Srg3 expression was largely 
mediated through activation of the Ras/MEK/ERK/ or PI3K pathway.  Hong et al (2004), 
reported BAF155’s involvement in a positive feedback regulatory loop with androgen 
receptor (AR) in developing mouse prostate.  This function of BAF155 involved no other 
members of the SWI/SNF complex and was fully functional in its participation in this 
regulation of AR in BRG1/BRM deficient C33A cells.  Recently, BAF155 was shown to 
affect insulin sensitivity by regulation of insulin-dependent gene expression via interaction 
with ADD1/SREBP1c, a transcription factor proposed to mediate regulation of insulin-
dependent gene expression (Lee, 2007).   
 As alluded to earlier, BAF155, along with fellow core member BRG1, becomes 
phosphorylated as the G2/M checkpoint is reached.   It is believed this interaction stabilizes 
the core to ensure proper functioning of the complex at this checkpoint.  Precisely how these 
cell cycle checkpoints function is not yet fully defined. It is known, however, that Cyclin E-
cdk2 complexes play an essential and rate-limiting role in the transition between G1 and S 
phase (Owen-Hughes, 1995; Resnitzky, 1994; Tsai, 1992; van den Heuvel, 1993) although 
the specific downstream targets of Cyclin E used to carry out the activity are poorly 
understood.  It is also known that Cyclin E is essential even in the absence of Rb suggesting 
another rate-limiting substrate exists for cyclin E-cdk2.  Emma Lees and co-workers have 
demonstrated an association between BAF155 with Cyclin E and BRG1 that, possibly among 
other functions, impedes the ability of BRG1 to induce growth arrest (Shanahan, 1999).  
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E. Specific aims of this dissertation 
 The importance of epigenetic and related chromatin remodeling complexes to cancer 
has established itself in the scientific consciousness; however the exact mechanism of how 
they function has not come into focus.  In some cases, like that of the SWI/SNF complex, the 
specific function of every member of the complex is not yet well understood.  It is known 
SWI/SNF affects the transcription of approximately 5% of the genome, but which 5%, and 
how that 5% is targeted is still largely unknown.  Understanding the function and association 
of each subunit will shed light on the targeting and exact function of the complex as a whole, 
and ultimately allow for attempts at correction when the system malfunctions.   The study 
presented here is designed to better define and shape the role of two core subunits of the 
SWI/SNF chromatin remodeling complex and their roles in tumor suppression.  It seems 
clear that while the BRG1 and SNF5 core members of SWI/SNF play a role in development 
and cancer, the involvement of BAF155 has not been characterized.  We present here, in the 
first aim, evidence of the potential of SWI/SNF core complex member BAF155 as a tumor 
suppressor.    
 While the tumor suppressor status of SNF5 is well established, its mechanism of 
tumor suppression is not.  A vital part of understanding the function of a tumor suppressor is 
in knowing the cell cycle pathways affected by its loss.  The second aim presented here 
attempts to determine if there exists a cooperative relationship between tumor suppressor and 
cell cycle regulator p53 and SWI/SNF complex core member SNF5. 
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CHAPTER 2 
 
MATERIALS AND METHODS 
 
A. Cell lines.  
  All cell lines were grown at 37oC in a 5% CO2 incubator with RPMI 1640 medium 
base supplemented with 10% FBS with the exception of SNUC2B which was grown in 
20% FBS.    Cell lines listed were acquired from ATCC unless noted otherwise.  Cell 
lines referred to in following chapters but listed here have been previously published and 
are detailed in the referenced publication.  SKOV3, SNUC2B (from Eric Knudsen lab, 
University of Cincinnati, OH), Normal human fibroblasts (NHF), U2OS (Trevor Archer 
lab, NIEHS, RTP, NC), MCF-7, and HepG2. 
 
B. Transfections.   
  Transfections of expression vectors were carried out by the Lipofectamine 2000 
(Invitrogen) or Effectine (Qiagen) method according to the manufacturer’s instructions.  
Selection, when used, was begun 24 hours post transfection by adding neo to the nutrient 
media for the described amounts of time, usually 10-14 days post transfection.  
Expression vectors used can be seen on table 2-1  
 
C. Western blots   
  Whole protein was extracted from trypsinized subconfluent cells washed once in 
PBS.  Total proteins were extracted using 8 mol/L urea as described previously.  Nuclear 
  
 
 
Table 2-1. : Content and source of expression vectors used in the examination of BAF155 
loss and function. 
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Table 2-1: 
 
Plasmid Content of plasmid Source 
pcDNA3/BAF155-
V5 
V5 tagged full length BAF155 Kind gift of Dr. Trevor Archer 
(Chen, 2005) 
pCMV/myc/nuc/ 
BAF155-∆2 
Myc tagged truncation mutant 
BAF155 
Kind gift of Dr. Trevor Archer 
(Chen, 2005) 
H2Bgfp GFP Kind gift of Dr. Erik Knudsen 
β-gal control vector β-galactosidase (control) CMV 
promoter 
Open Biosystems RHS3708 
pCMV Empty vector control Kind gift of Dr. Trevor Archer 
pEGFPBAF155 c-terminus-GFP tagged full length 
wild-type BAF155. CMV 
promoter, no selection 
Gift of Dr. Erik Knudsen 
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      extracts were obtained by first washing the cells before they were pelleted, incubated 
with hypotonic buffer for 10 min on ice followed by manual homogenation (glass 
douncer) and centrifugation.  Protease inhibited nuclear extract buffer was then added to 
the homogenized pellet before sonication and a second homogenation.  Cell extract was 
then centrifuged for 30 min at 4oC before clear supernatant is dialyzed for 4.5 hours to 
pH 7.9.  Protein concentration was quantified by the Bio-Rad protein assay (Bio-Rad 
Labs, Hercules, CA) per manufacturer’s instructions.  Proteins (30ug) were separated by 
electrophoresis on 4-20% or 7.5% SDS-polyacrylamide gels (Cambrex, Rockland, ME) 
and electrotransferred onto Immobilon-P membranes (Millipore, Billerica, MA) 
according to the manufactures’ instructions for Biomax ML film (Kodak, Cedex, France).  
Commercial antibodies used are detailed in table 2-3 
 
D. DNA extraction from cell lines for sequencing 
   DNA was extracted using the Qiagen DNeasy kit for extraction and purification of 
genomic DNA.  For cDNA, mRNA was first extracted with Qiagen RNeasy kit, then RT-
MMLV kit was used to reverse transcribe cDNA according the manufacture’s 
instructions. 
 
E. Sequencing 
   Sequencing primners. were designed according to known BLAST sequences of 
BAF155 to amplify several sections of several hundred base pairs each of cDNA from 
genomic DNA. Sequencing of individual exons was done as well accoding to the primers 
in the table below.  BAF155 sequencing samples were submitted to UNC-CH sequencing 
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facility according to their instructions.  Details of all primers used can be found on table 
2-3 
 
F.  Bromodeoxyuridine staining.  
     Inhibition of BrdU incorporation was performed as previously described (Strobeck, 
2002).  Briefly, cells were treated with 1:1000 BrdU (Amersham Biosciences) 36 hours 
after transfection and stained with 1:50 anti-BrdU antibody (Accurate Chem & Sci. Corp.) 
12 hours later.  BrdU-positive cells were counted in at least 100 GFP-positive cells.  Error 
bars (standard deviation) were calculated from at least three independent experiments. 
 
G. Protein Stability   
  Lactacystin Treatment was as follows.  Lactacystin (3-(4-iodophenyl)-2-mecapto-(Z)-
2-propenoic acid) (#426100 from Calbiochem) was dissolved in dimethysulfoxide 
(DMSO) with the final concentration of DMSO that cells were exposed to being no 
greater than 0.2%.  Lactacystin/DMSO mix  or DMSO alone (as a control for the effects 
of DMSO) was added to the standard media for each cell line and remained on cells for 
the times indicated in each figure (4-32 hours) at which time 8 molar urea protein 
extractions were carried out and protein ran out via Western blot. 
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Table 2-2 :  Primer sequences for primers used in sequencing of BAF155 gene in cDNA as 
well as genomic DNA of SKOV3 and SNUC2B cell lines and primer sequences for 
genotyping of mice 
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Table 2-2:  
 
Name Primer sequence (forward) Primer sequence (reverse) 
122F CGCAGGCCTAGCTGTTTATC  
290F  GTGCAGCTTCTTCAGTTCC 
1F1 ACGACGGGCTGCGACGATG  
2F2 TTGGTGCAGAACAATTGTTTGACC  
1R1  CACCGAATCCAGCTGGGGAC 
2R2  CAAGAATGTGACATAAGGCGC 
9R1  CGTGGAGGTTCCCTGCATC 
7R  GAGTGCTGGTGTGCCTGTTG 
16R  TCCTAAGATGTTTCCTGGCATTG 
16F CAATGCCAGGAAACATCTTAGGA  
3F GCCAGTCAGAAGTCCAGAAAGAAG  
660F CACATTTACCCATATTCTTCCTCAC  
1001R  TGCTTTTCTATCTCTTCTTTCTGGA 
1167F CCAACACCTGTACCCAATATAGAAG  
2822R  GGAAACTATCATGGACAGAGAGAAA 
425F CAAGTATAAAAATGAACAGGGATGG  
1562R  ATACTCTTGGGGGTTTAGACGATAC 
859F TGGACACTGATATTTTCAATGAATG  
744R  AATGCACTAACACTTGCTTCTCTTT 
2496F GAAAAGGAACAGGATAGTGAAGTGA  
1191R  TCTTTCTTTAGGTTCACATTTTTGG 
2833R  TCTAGAGCTTCTTTCTCTCTGTCCA 
2496R  TCACTTCACTATCCTGTTCCTTTTC 
1538F GTATCGTCTAAACCCCCAAGAGTAT  
1866R  AGTAAATGTCAGTACGGAGACCAAA 
1812F CAGATGCTAAATTTTCCTGAGAAAA  
122R  TCGATAAACAGCTAGGCCTGCG 
3340R  CTGCATCTTCCAGGCTAAGG 
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290R  TTCCTGGAACTGAAGAAGCTGCACC 
3123R  CTGCAACAGTGGGAATCATG 
545F ATCTCGAATGGATCGTAATG  
EXON FORWARD PRIMER REVERSE PRIMER 
Exon 1  TTGCATATTCGTGGTTCTAAATTC GAGGCCAGCTGCCGCCT 
Exon 16  GCACATGAAGTTGATTCTTTAG CAACCCCTAAATGGCATAAC 
Exon17  AGAGGCTAACTCAGCCATTT GCCATTTGTTACTATCCAGTC 
Exon 18  CTGAGCTCCATCTTCAGCAT ACTAAGATGTGCTGGATTGC 
Exon 19  CTGAGCTCCATCTTCAGCAT GGTGACACACAGCGAGACC 
Exon 20 TCTTGTTACCTGACATGAAAGC ATGAATGTAACGGCTGGTAA 
Exon 21  AAGTTAGATTGCTGTTCCAT TATACTGATCATTGTACTCACT 
Exon 22  CAGACACTCTCACAGCTGTA GGTCTGAAAGGCATGCTATC 
Exon 23  CGAGCTGTTCTCTACAAGTCAC AAGTGTAGCCACCAGCATTA 
Exon 24  GAGAGTGGGCACGCTAGTA CAATACGAGCATTCATGCCT 
Exon 25  AGCTTGAATGATCTTGTACC TGGAAAAGTGACCAAGGTT 
Exon 26  CTGGTGTCATTTCTTCCACT CCCTAAATCTCACATGCCTAC 
Exon 27  GTTGATCCCTTTCTTACACCC AACGGACCCTGAGATAATGC 
Exon 28  TCCAGCAATAACGAGTTACTC CACGGCTTGGAGCTGTGAG 
Product Forward primer Reverse primer 
Wild type 
SNF5 
CAGGAAAATGGATGCAACTAAGAT CACCATGCCCCCACCTCCCCTACA 
Mutant 
SNF5 
GGCCAGCTCATTCCTCCCACTCAT CACCATGCCCCCACCTCCCCTACA 
Wild type 
p53 
ACAGCGTGGTGGTACCTTAT TATACTCAGAGCCGGCCT 
Mutant    
p53  
TCCTCGTCGTTTACGGTATC TATACTCAGAGCCGGCCT 
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H. Immunoprecipitation 
   Cells were lysed in high-salt buffer (20mM Tris-HCl [pH 7.5], 400 mM NaCl, 1 mM 
EDTA, 0.5% NP-40) containing a protease inhibitor cocktail.  A whole-cell extract (500 
ug) was first diluted with an equal volume of dilution buffer (lysis buffer without NaCl), 
brought to 500ul by adding IP buffer (lysis buffer with 200 mM NaCl), and incubated with 
approximately 3 to 5 ug of antibody at 4oC overnight.  The incubation was continued for an 
additional 2 hours after the addition of 20ul of protein A/G plus-agarose bead slurry (Santa 
Cruz Biotechnology, Santa Cruz, CA). Agarose beads were washed four times with IP 
buffer and eluted into 40ul gel loading buffer by heating at 95oC for 5 min.  The bound 
proteins were separated by SDS-PAGE. 
 
I. Northern blotting   
      Expression of BAF155 mRNA was determined by standard Northern blot analysis. 
Total cellular RNA was extracted using the Qiagen RNeasy kit.  Fifteen micrograms of 
total RNA were run on 1% agarose/formaldehyde gels and were gravity transferred to 
positively charged nylon membranes.  The membranes were stained for ribosomal 28s 
proteins for equal loading.  BAF155 probes were 32P-radiolabeled by random primer 
extension, hybridized to membranes, and subsequently rinsed to remove nonspecific 
radioactivity. Hybridization bands were visualized by autoradiography.  
 
J. Real-time PCR 
       Real-time quantitative reverse transcriptase polymerase chain reaction: Total RNA was 
isolated from each cell line using the Qiagen RNA extract  kit (Qiagen, Valencia, CA) 
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according to manufacturer’s protocol and analyzed by the TaqMan (Applied Biosystems, 
Foster City, CA) quantitative real-time reverse-transcription PCR using β-actin as a 
reference gene in each reaction..  Primers used were as follows: BAF155: 
CACCCCAGCCAGGTCAGAT (forward) & TGCAACAGTGGGAATCATGC (reverse); 
BAF170: GAGAAGCACTGGAGTATCAGA (forward) & 
ATCTCCGCATACTTCAGCTG (reverse).  The probes used for BAF155 and BAF170 
were CAGGCCCAGGTTCCATGATGCCCG and 
CAGCAGCTCCTGGCCGACAGACAAG respectively.  
 
K. Apoptosis detection - TUNEL Assay 
       Apoptosis via DNA fragmentation was measured using the “In Situ Cell Death 
Detection Kit, TMR red” from Roche (catalog # 12 156 792 910).  The kit was used 
according to manufacturer’s instructions following transfection with plasmids, at times 
post-transfection as indicated in each figure.  At least 200 cells were counted in each of at 
least 3 independent experiments for each condition.                       
 
L. Senescence detection via β-galactasidase 
       Senesence-associated β-galactocidase was carried out as previously described (Dimri et 
al 1995) with modifications of Kramer et al 2001. Briefly cells were washed with PBS, 
fixed for 3 minutes with 3% formaldehyde/PBS, washed three times with PBS, and 
incubated overnight in a 37oC incubator in SA-β-gal solution (5mM potassium 
ferrocyanide, 5mM potassium ferricyanide, 2mM mgCl2, and 1mg/ml 5-bromo-4-chloro-3-
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indolyl-β-D-galactoside (X-Gal in PBS).  Plates were visualized with bright field 
microscopy on a Zeiss 1M 35 microscope. 
 
M. Generation and Maintenance of mouse colony 
     Snf5+/- mice were originally generated by Dr. Charlie Roberts as described in: Robersts, 
2000.  The p53+/- mice were originally generated by Dr. Tyler Jacks as described in 
Jacks,1994.   Mice were monitored twice a week for 24 months or until a tumor was 
observed or evidence of a tumor (paralysis, swelling, extreme lethargy, etc).  
 
N. Histology of mouse tissues  
  Tumor samples and selected tissues were fixed in 10% buffered formalin phosphate and 
processed for paraffin embedding.  Slides are cut and left unstained for future 
immunohistochemistry or stained for eosin and hematoxilin by UNC’s Histopathology Lab.  
 
O. Immunohistochemistry  
   IHC analysis carried out using the Vectastain Elite ABC Kit from Vector 
Laboratories (PK-6100), following manufacturer’s directions.  Antibody diluent buffer 
from Biomeada.   Antigen retrieval citra plus solution from BioGenex (cat # HK081-5K).  
Liquid DAB substrate system from Innovex biosciences (product # NB314SBD).  The 
immunohistochemical staining of the mouse tissue array for p53 was carried out by The 
Laboratory of Experimental Pathology Immunohistochemistry Group at NIEHS, RTP, NC.  
All antibodies used are included in the table below. 
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P. DNA extraction for mouse genotyping 
   Genomic DNA was extracted from mouse toes and tumors for genotyping using the 
Qiagen DNeasy Kit for animal tissues.  DNA was extracted/purified from vectors using 
plasmid prep kits from Qiagen followed by enzymatic digestion at 37oC for one hour.   
 
Q. Genotyping 
  All PCR recactions were carried out using EasyStart 0.5mL PCR tubes 
(MolecularBioProducts #6022).  The following additions were made to the EasyStart tube: 1-
3ul of DNA extracted from mouse toes, taq DNA polymerase, specific primers for the mutant 
or wild type allele, and water.  Primer details can be found on table 2-2    
 
R. Antibodies  
  All antibodies were used per manufacture’s instructions unless otherwise specified in 
figure legend or table 2-3. Detail of antibodies used for western blot and 
immunohistochemistry can be seen on table 2-3 
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Table 2-3:  Description and source of antibodies used for western blot and 
immunohistochemistry 
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Table 2-3:  
 
ANTIBODY Brief Description Source 
BAF155 (H-76) Rabbit, to AA 889-913 Santa Cruz sc-10756 
BAF155 (DXD7) Mouse monoclonal, to AA 
591-608. does not react 
with BAF170 
Sigman B5186 
Actin Rabbit polyclonal,  Sigma A2066 
BRG1 (J1) rabbit polyclonal Kind gift of W. Wang 
BRG1 (G-7) mouse monoclonal Santa Cruz sc-17796 
BRM Rabbit polyclonal Abcam ab15597 
SNF5 Rabbit polyclonal Gift of Anthony Imbalzano 
SNF5 Mouse monoclonal Transduction Labs, 612110 
BAF57 Rabbit polyclonal Gift of Karen Knudsen, Univ. of 
Cincinnati, OH 
BAF170 Rabbit polyclonal Gift of W. Wang 
Vimentin Rabbit polyclonal Biomeda V2009 
B220/CD45R Mouse monoclonal BD Pharmingen 550286 
CD3 Rabbit polyclonal Cell Marque CMC363 
S100 Rabbit polyclonal DAKO Z0311 
P53 (CM5) Rabbit polyclonal Novacastra Labs NCL-p53-CM5p 
GFP Mouse monoclonal Santa Cruz (sc-9996) 
c-jun Rabbit polyclonal Oncogene Science PC07 
Ubiquitin Mouse monoclonal Santa Cruz sc-8017  
Cyclin E (M-20) Rabbit polyclonal Santa Cruz sc-481 
c-myc (9E10) Mouse monoclonal Santa Cruz sc-40 
V5 Mouse monoclonal Invitrogen R961-25 
PAI-1 Mouse monoclonal Oncogene IM29L 
PML Mouse monoclonal Santa Cruz sc-966 
PARP Rabbit polyclonal Roche 1 835 238 
P21 (WAF1) Mouse monoclonal Oncogene OP64 
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 CHAPTER 3 
Identification of an Additional Core Member of the SWI/SNF 
Complex, BAF155/SMARCC1, as a Human Tumor Suppressor 
Gene 
 
A. Abstract 
 Recent studies have established that two core members of the SWI/SNF chromatin 
remodeling complex, BRG1 and SNF5/INI1, possess tumor-suppressor activity in human and 
mouse cancers.  While the third core member, BAF155, has been implicated by several 
studies as having a potential role in tumor development, evidence for its tumor suppressor 
activity has remained unclear.  Therefore, we screened a large number of human tumor cell 
lines for BAF155 deficiency.  We identified 2 cell lines, SNUC2B colon carcinoma and 
SKOV3 ovarian carcinoma, displaying a complete loss of protein expression while 
maintaining normal levels of mRNA expression.  The SKOV3 cell line possesses a 
hemizygous 4bp deletion that results in an 855AA truncated protein, while the cause of the 
loss of BAF155 expression in the SNUC2B cell line remains unknown.  However, the lack of 
detectable BAF155 expression did not prevent assembly of the SWI/SNF complex, or effect 
sensitivity to Rb-mediated cell cycle arrest.  Re-eexpression of full length but not a truncated 
form of BAF155 in the two cancer cell lines leads to reduced proliferation and colony 
forming ability.  This arrest appears to result from induction of p21WAF1/CIP1 expression 
followed by replicative senescence and not apoptosis.  Collectively, these data suggest that 
loss of BAF155 expression represents another mechanism for inactivation of SWI/SNF 
complex activity in the development in human cancer.  Furthermore, loss of BAF155 causes 
a slightly different phenotype than loss of either BRG1 or SNF5/INI1.  Finally, our results 
indicate that the c-terminus proline-glutamine rich domain plays a critical role in the tumor 
suppressor function of this protein.   
 
B. Introduction 
 A new era of cancer research is underway with the realization that the initiation and 
regulation of cancer involves more than the identification of oncogenes or tumor suppressor 
genes.  The field of epigenetics has exploded in recent years with multiple studies 
demonstrating the involvement of DNA methylation and chromatin modification in cancer 
development.  Both mechanisms regulate gene transcription by controlling the access of 
transcription factors to DNA.  Chromatin disorders have been implicated in the devastating 
effects of solid tumors as well as myeloid leukemia, Rubinstein-Taybi Syndrome, and 
malignant rhabdoid tumors.  
 The proper functioning of the SWI/SNF chromatin remodeling complex is vital to 
appropriate cell cycle control and tumor suppression.  Despite the seemingly small (5%) 
amount of genes whose regulation the complex affects, they are widely dispersed throughout 
the genome with more repression than activation (Sudarsanam, 2000).  The ubiquitously 
expressed multi-unit complex is composed of a small core including BRG1 or BRM, 
SNF5/INI1/BAF47, BAF155, BAF170 and variable associated complex members depending 
on cell type and stage of development.  Most core members are vital to life and essential to 
development as homozygous knockout mice show embryonic lethality (Bultman, 2000; 
Reyes, 1998; Kim, 2001).   
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 Either BRG1 or BRM serve as the catalytic subunit of the complex.  Approximately 
ten percent of human cancer cell lines show mutations or deletions of these genes (Reisman, 
2003).  Another core member, SNF5/BAF47/INI1, is an established tumor suppressor gene 
that is deleted in almost all MRTs (Biegel, 1999).  The absence of SNF5 protein provides the 
diagnostic marker for these cancers.  Genetically engineered mice also provide evidence for 
the tumor suppressor activity of these genes.  Mice heterozygous for BRG1 develop tumors 
resembling breast adenocarcinomas (Bultman, 2000), while heterozygous SNF5 mice 
develop rhabdoid tumors histologically similar to their human counterparts (Roberts, 2000; 
Klochendler-Yeivin, 2000; Guidi, 2001).  Several studies have implicated that the SWI/SNF 
complex acts as a tumor suppressor via its role in cell cycle regulation.  The SWI/SNF 
complex can control cellular proliferation by its association with known cell cycle checkpoint 
genes, such as cyclin E, p21, p53, and p16 (Hill, 2004; Lee, 2002; Bochar, 2000, Gartel, 
2003). 
The unique contribution of BAF155, another core member, to the complex remains 
ill-defined.  Initially isolated as a gene highly expressed in thymus/low in periphery, BAF155 
actually shows ubiquitous expression similar to the rest of the SWI/SNF complex.  Also 
known as SWI3 in yeast, SRG3 (SWI3 related gene) in mouse, and MOIRA in drosophila, 
BAF155 has been implicated to have a significant role in development.  In mice, SRG3 is 
essential to early embryogenesis, as well as having a specific requirement for brain 
development and T-cell differentiation (Kim, 2001).  SRG3 also can be induced by androgen 
and subsequently transactivate AR in the prostate (Hong, 2004).   Reduction of SRG3 leads 
to a significant inhibition of GC-induced apoptosis (Vacchio, 1999; Ashwell, 2000; 
Pazirandeh, 2002).  BAF155 has also been implicated in the regulation of cyclin E activity 
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(Shanahan, 1999).  Little is known, however, of the role of BAF155 in cancer related 
functions.   
 This study sheds light on the potential tumor-suppressor functions of BAF155 by 
characterizing 2 human tumor cell lines that lack BAF155 expression.  Our studies 
demonstrate that reexpression of exogenous full length BAF155 induces senescence in these 
cell lines.  In contrast, exogenous expression of BAF155 on 2 human cell lines with 
endogenous expression had no little or no effect on cell growth.  Furthermore, truncation of 
the c-terminus of BAF155 caused a significant loss of its tumor suppression activity.  Our 
results establish another member of the SWI/SNF complex as a tumor suppressor gene that 
may contribute to its regulation of the cell cycle and cellular senescence. 
  
C. Results 
1.  Loss of BAF155 expression in two carcinoma cell lines.    
  To gauge the frequency of BAF155 loss as well as to generate a cell culture model 
system to study BAF155 functions, we screened >100 human cancer cell lines by western 
blot for BAF155 expression.  We identified two carcinoma cell lines lacking BAF155 protein 
(Figure 3-1A): SKOV3, an ovarian carcinoma cell line, and SNUC2B, a colorectal carcinoma 
cell line.  Initial screening of nuclear extracts from these cells showed that other complex 
members, including BRG1 and SNF5, were present.  We also screened whole cell extracts to 
determine whether BAF155 still appeared in the cytoplasm.  We did not observe BAF155 
expression under any protein extraction conditions in these two carcinoma cell lines.  Both 
cell lines contained a full complement of other SWI/SNF complex members, although 
SNUC2B’s BRG1 ATPase domain has two point mutations (Wong, 2000). 
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 2. Loss of BAF155 in two carcinoma cells lines is not due to loss of gene expression or 
proteasome degradation.   
 To determine the reason for the lack of BAF155 protein expression in the two 
deficient cell lines, we assessed mRNA levels by northern blot analysis.  As shown in Figure 
3-1B, both cell lines expressed comparable levels of BAF155 mRNA to BAF155 positive 
cell lines.  Because of the strong homology between BAF155 and BAF170, we confirmed 
these results with real time PCR.  We did not observe any reduction in BAF155 or BAF170 
expression by this method (Figure 3-1C).   
 We next determined whether the absence of BAF155 protein resulted from increased 
protein degradation.  Cells were treated with lactacystin for up to 36 hours (inhibiting the 
degradation of ubiquitinated proteins), whole proteins was harvested and analyzed by 
western blot for BAF155 expression.  Expression of c-jun, a protein with a rapid degradation 
rate, was included as a positive control.  As shown in Figure 3-1D, c-jun protein levels 
increased after lactacystin treatment, accompanied by an increase in ubiquinated proteins.  
However, we did not observe reexpression of the BAF155 protein. 
 
3. Ovarian carcinoma cell line SKOV3 posesses a truncation mutant BAF155.   
 Upon sequencing individual exons of BAF155 in the two cells lines, SKOV3 revealed 
a 4 base pair deletion in exon 24 leading to a stop codon at 2566bp (figure 3-2).  This 
mutation would yield a truncated protein of 855 amino acids, instead of the full length 
protein of 1105AA.  The loss of the last 250 amino acids would remove the leucine zipper 
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and proline-glutamine rich domains as well as the antibody binding site.  Therefore, we 
cannot rule out production of a truncated protein by the SKOV3 cell line.  The primary  
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Figure 3-1:  Two carcinoma cell lines SKOV3 and SNUC2B lack BAF155 protein  
          expression.  
 
(A) Western blot loaded with 30ug of nuclear extract from cell lines, actin-related 
BAF53 serves as the loading control.   
 
(B) Northern blot (B) and Quantitative PCR (C) analysis reveals both cell lines 
lacking BAF155 expression retain comparable amounts of BAF155 and 
BAF170 RNA levels as other cancer cell lines. A) thirty micrograms of 
mRNA of each cell line were analyzed by northern blot and probed with 
BAF155 cDNA probe.  18S and 28S bands serve as loading control 
indicators. 
 
   
(C) Both cell lines lacking BAF155 protein expression were analyzed 
quantitatively for amounts of BAF155 and BAF170.  Graphed values are 
relative quantities as compared to actin.  
 
(D) BAF155 protein is not degrated by the ubiquitin-proteasome pathway in either 
carcinoma cell line lacking BAF155 expression.  Increased time under 
lactacystin treatment leads to a measurable accumulation of proteins degraded 
by the ubiquitin-proteasome pathway as demonstrated with c-jun.  Mock 
treatment with DMSO revealed the accumulation is due specifically to the 
lactacystin treatment/ degradation inhibition 
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Figure 3-2: Sequence of exon 24 of SKOV3 ovarian carcinoma cell line lacking protein 
expression.    
 
Individual exons were amplified by PCR, purified and sent to UNC-CH Genome Analysis 
Facility for analysis.  This 4 bp deletion mutation leads to a aberrant stop codon at 2666-
2669, yeilding an 855 amino acid truncated BAF155 protein.  Result was confirmed three 
times. The black sequence represents the published BAF155 wild type sequence.  The blue 
sequence represents the sequence of exon 24 of BAF155 genomic DNA in the SKOV3 cell 
line. 
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GAAGAAAAGGAGACTGAAGAGAACAAAGAACTCACTGATACATGTAAAGAA 
   E      E      K      E      T     E     E      N     K      E      L     T     D      T     C      K      E   
GAAGAAAAGGAGACTGAAGAGAACAAAGAACTCACTGATACATGTAAAGAG 
   E      E      K      E      T     E     E      N      K     E      L     T     D      T     C     K     E 
 
 
 AGAGAAAGTGATACTGGGAAGAAGAAAGTAGAACATGAAATTTCCGAAGGA 
     R     E      S     D      T     G     K     K      K     V     E      H     E      I       S     E     G      
AAAGTGATACTGGGAAGAAGAAAGTAGAACATGAAATTTCCGAAGGAAATG 
    K    V      I      L      G      R     R      K   STOP 
 
 
AATGTTGCCACAGCCGCAGCAGCTGCTCTTGCCTCAGCGGCTACCAAAGCCA 
    N    V     A     T     A      A     A      A    A     L    A     S      A     A     T    K     A     
TTGCCACAGCCGCAGCAGCTGCTCTTGCCTCAGCGGCTACCAAAGCCAAGC 
 
 
AG 
K 
 
 
 
FIGURE 3-2 
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sequence of SNUC2B has not yielded a mutation.  We are currently sequencing the 
untranslated regions of mRNA to lookfor potential abnormalities in protein translation 
signals. 
 
4.  BAF155-induced growth inhibition of carcinoma cells via senescence.    
 We next assessed the effects on cell growth after reexpression of BAF155 in the cell 
lines lacking endogenous expression.  We used expression vectors that coded for either a 
full-length protein or one with a 332 amino acid deletion of the c-terminus (Figure 3-3A).  
We have previously shown that the c-terminal deletion abrogates BAF155’s ability to 
regulate the stability of another complex member, BAF57 (Chen, 2005).  We first examined 
the effects of BAF155 reexpression on DNA synthesis after 48 hours by measuring BrdU 
incorporation into nuclei.  Re-expression of wild type and mutant tagged-BAF155 protein 
(Figure 3-3B) resulted in different outcomes for the BAF155-expressing Hela and U2OS cell 
lines versus the BAF155 deficient SKOV3 and SNUC2B cell lines (Figure 3-3C).  As shown 
in Figure 3-3C, BAF155 null cell lines were inhibited for BrdU incorporation in response to 
full-length wild type BAF155 transfection with no inhibition with mutant BAF155.  In 
contrast, expression of either form of BAF155 in the Hela or U2OS cells had no effect 
(Figure 3-3C).  These results indicated that a block in cell cycle progression was induced 
within 48 hours following BAF155 expression.   
 We then assessed BAF155 effects upon long-term proliferation by a colony-forming 
assay. Colony forming assays showed a marked reduction in colony forming ability in 
BAF155 null cells after wild type BAF155 reexpression, but not when transfected with 
mutant BAF155 (Figure 3-3D).  No effect on colony forming ability was seen in Hela cells 
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endogenously expressing wild type BAF155, although a partial reduction of colony forming 
ability was observed in U2OS cells. 
 To determine if the inhibition of growth was due to a senescent or apoptotic response, 
we investigated typical markers of each of these events in both cell lines at several time 
points following reexpression of BAF155.  No increase in fragmented DNA particles, 
characteristic of early to middle apoptosis, was seen via TUNEL staining at 2, 4, or 7 days 
following BAF155 expression (Figure 3-4).  In contrast, approximately 15-20% of the 
BAF155-deficient cell line expressed the senescence marker, ß-galactosidase by 10 days 
(data not shown).  These results are similar to those observed upon reexpression of BRG1 in 
BRG1/BRM-deficient human tumor cell lines (Dunaief, 1994; Shanahan, 1999; Strober, 
1996; Wong, 2000; Hendricks, 2004). 
 64
  
 
 
Figure 3-3:  Demonstration of BAF155 growth arrest ability.  
 
 (A) Schematic of BAF155 expression vector contents used for re-expression studies 
in this and subsequent figures.  Note the striped boxes indicate the identifiable tag for each 
insert.  The delta-2 mutant BAF155 also has added a nuclear localization signal.  
 
 (B) Western blot demonstrating expression of tagged full length BAF155 (V5) as well 
as mutant BAF155 (∆2) 2 days post-transfection.  30ug whole cell extract was loaded. Actin 
acts as loading control 
 
 (C) BrdU incorporation: Cells were co-transfected at a 1:10 ratio of GFP: vector of 
interest, one of the following: empty vector control, full length BAF155-V5 tag, truncation 
mutant BAF55 ∆2.   Bar values are a ratio of GFP positive cells to BrdU positive cells. 
Results normalized to empty vector control amounts.   Values graphed are an average of 3 
independent experiments.      
 
 (D) Results of the 14 day colony forming assay.  Cells were carried under selection 
for 12 days beginning 2 days post-transfection.  Bar values were calculated by a ratio of 
stained cells present at day 14 to the empty vector control transfected cells for each cell type.    
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5. The SWI/SNF complex still forms in cells lacking BAF155 expression and retains 
the ability to support Rb-mediated cell cycle arrest.  
 We next asked whether the absence of BAF155 affected formation of the complex.  
The core components, as well as BAF57, still co-immunoprecipitated in cells with or without 
BAF155 expression (Figure 3-5A and data not shown).  We then determined whether the 
complex could still contribute to Rb-mediated cell cycle arrest in cells without BAF155 
protein.  Both cell lines were found to be Rb sensitive, arresting in G0, following p16INK4A 
expression (Figure 3-5C).  Upon infection with p16INK4A encoding adenovirus (demonstrated 
in Figure 3-5B), accumulation of SKOV3 cells can be in G0/G1 (Figure 3-5D). BrdU 
labeling reveals these cells never reach S phase (Figure 3-5C).  This data shows the complex 
can still form in  
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Figure 3-4: TUNEL Apoptosis detection.   
 
Cells were analyzed 48 hours post co-transfection with GFP and one of the following: empty 
vector control, V5 tagged full length BAF155, or myc tagged ∆2 truncation mutant BAF155.  
A ratio of TUNEL positive (broken DNA ends = apoptosing) cells to GFP positive cells 
(presumed to express BAF155 as well) were averaged and normalized to empty vector 
control cell. 
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 Figure 3-5 
 
 (A)  SWI/SNF complex subunits associate with one another despite lack of BAF155.  
western blot following immunoprecipitation with antibodies listed above lanes and western 
blot probed by antibodies listed to the right of each lane. 
 
 (B)  SKOV3 and SNUC2B cells were infected with GFP or p16ink4a encoding 
adenviruses. Western blot run from protein extracted 36 hours later.  
  
 (C)   36 hours post infection with GFP or p16ink4A encoding adenviruses cells were 
analyzed for incorporation of BrdU and graphed as a ratio of BrdU positive cells in the GFP 
control cells for each cell line. 
 
 (D)    Cells were infected with GFP or p16ink4A encoding adenoviruses for 36 hours, 
cells were harvested, fixed with ethanol, and stained with propidium iodide (PI).  Cell cycle 
distribution was then determined by flow cytometry. DNA content is plotted against cell  
number.  
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cells lacking BAF155 and maintain Rb-mediated cell cycle arrest.  This result implies Rb 
mediated cell cycle arrest does not depend on the presence of full length BAF155.      
 
D. Discussion 
 The previously conceived notion of cancer etiology being nature OR nurture has been 
replaced with the knowledge that carcinogenesis often includes both genetic and 
environmental factors.  This paradigm becomes more obvious as the field of epigenetics 
comes into focus to reveal its importance in cancer development and progression.  The 
chromatin remodeling arm of epigenetic modification is carried out by many diverse 
complexes, including the SWI/SNF complex.  In yeast, a fully-functional SWI/SNF complex 
includes all complex members (Laurent, 1991; Peterson and Herskowitz, 1992) and the loss 
of any component causes subtle changes in complex activities.  In mammalian cells, the 
SWI/SNF complex associates with and possibly regulates cell-cycle control genes including 
pRb (Dunaief, 1994), other RB family members (Fryer and Archer, 1998; Singh., 1995; 
Strober., 1996; Trouche, 1997), BRCA1 (Bochar, 2000), p21 (Chai, 2006) and Cyclins E and 
A (Zhang, 2000).  A loss of any SWI/SNF member could contribute to the tumorigenicity of 
a cell given these connections to Rb function as well as other cell cycle regulators.  This is 
indeed true for SWI/SNF complex member SNF5/INI1, as loss of SNF5 activity appears to 
abrogate the Rb signaling pathway through a block in p16INK4A induction or increased 
expression of cyclin D1.   
 In this report, we have revealed a role for another core SWI/SNF member, BAF155, 
in cell cycle checkpoint control and likely tumor suppression, via its leucine-zipper domain.  
We show expression of exongenous BAF155 in carcinoma cells lacking BAF155 
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consistently produces replicative senescence.  This effect was also seen with low levels of 
BAF155 expression in the stable clones two weeks post-transfection.  This low level of 
exogenous BAF155 was sufficient to cause substantial inhibition of colony forming ability as 
well as BrdU incorporation, and leads to an accumulation of cells in G0/G1 as determined by 
flow cytometry.  These data indicate a vital (direct or indirect) role for BAF155 in the control 
of carcinoma cells SKOV3 and SNUC2B.  The leucine zipper or proline/glutamine rich 
domain of BAF155 would seem to control this effect, as transfection with the ∆2 mutant 
lacking these domains inactivated its ability to suppress growth in the two carcinoma cell 
lines.    
 BAF155 is the third core member of the SWI/SNF complex to demonstrate tumor 
suppressive capabilities related to cell cycle control.  Table 3-1 summarizes the tumor 
suppressive capabilities of the core members of the SWI/SNF complex.  All core members 
are required for the basic task of remodeling nucleosomes, but the necessity for their 
presence in specific tumor suppressive functions of the complex varies.   Rb-mediated cell 
cycle arrest requires only the catalytic core subunits BRG1/BRM, the specific functions 
served by SNF5 and BAF155 are dispensable for this particular tumor suppressive activity of 
the SWI/SNF complex.  However, reexpression of any one core member above does induce 
growth arrest via senescence, a key characteristic of most tumor suppressors.   This implies 
SWI/SNF complex may participate in more than one pathway to halt cell cycle progression.   
Additional mutational or inactivation studies are required to determine the pathways SNF5 
and BAF155 operate through to halt tumor cell progression. 
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Table 3-1:   Summary of the tumor suppressor capabilities of SWI/SNF core members.  Data 
compiled from this and previous studies as discussed in the text.  
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SWI/SNF 
core subunit 
Required for Rb-
mediated arrest? 
Can cause 
growth arrest?
Induces 
senescence? 
Involved in 
Apoptotic 
signaling? 
BRG1/BRM YES YES YES NO 
SNF5 NO YES YES NO 
BAF155 NO YES YES NO 
 
 
Table 3-1 
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 The lack of protein expression in SNUC2B without a mutation in the primary 
sequence or apparent degradation by the proteasome can be reconciled a few ways.  The 
region of chromosome 3 where BAF155 is found is home to a cluster of suspected tumor 
suppressor genes.  It is of note that it only rarely (only 5 of >200 primary human cancers) 
that somatic mutations have been found in 3p21 genes (Burbee, 2001; Dammann, 2003) 
although these genes are inactivated in the many cancers (Table 3-2).   Further, the non-
expressed but non-mutated 3p21 genes are found inactivated by other epigenetic 
mechanisms, such as chromosome instability, aneuploidy, promoter methylation, 
haploinsufficiency, altered RNA splicing, or defects in transcriptional, translational, or post-
translational processes.  Some are inactivated by rather exotic epigenetic means.  For 
example, the FUS1 gene has detectable mRNA but no primary sequence mutation detectable, 
nor any protein detectable either, by western blot, or IHC, or microtissue array; similar to 
BAF155 in SNUC2B.  Also, like so many 3p21 genes, FUS1 is a likely tumor suppressor 
gene, shown to be lost in >50% of lung cancers cell lines tested.  It was eventually 
discovered that wild type FUS1 could be found as an N-myristoylated protein.  Significant 
loss of expression or a myristoylation defect of the FUS1 protein was found in deficient lung 
cancer cell lines (Uno, 2004). 
 A more extensive proteasome-degradation inhibitor may be necessary ensure that 
degradation is not the cause of BAF155 protein absence in SNUC2B.  however there may be 
another reason. 
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Table 3-2:  Summary of multiple primary tumors and cancer cell lines displaying genetic 
abnormality in the 3p21 area of chromosome 3.   
 
Adapted from Ji et al, (2005) 
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 Primary Tumor 
Site 
% Showing Genetic 
Abnormality in 3p21 
References 
Lung 65-95 Lerman, 2000; Zabarovsky, 2002; Minna, 2002; 
Wistuba, 2001 
Breast 30-87 Miller, 2003; Maitra, 2001; Yang, 2002 
Head and Neck 30-69 Chakraborty, 2003; Glavac, 2003; Riazimand, 
2002 
Ovary >50 Manderson, 2002; Simsir, 2001 
Cervix/ Uterus 40-90 Acevedo, 2002; Dellas, 1999; Herzog, 2001; 
Senchenko, 2003; Tzai, 2003 
Colon/ rectum 14-33 Goel, 2003; Yashiro, 2001 
Pancreas 35-45 Hessman, 1999; Iacobuzio-Donahue, 2004 
Esophagus 13-55 Hu, 2000; Kuroki, 2003; Mueller, 2000; Shimada, 
2000; Wei, 2002 
Renal cell 45-87 Velickovic, 2001; Chino, 1999 
Bladder 25-60 Li, 1996; Reznikoff, 1996 
Nasopharyngeal 79-90 Liu, 2003; Lo, 2002; Lo, 2000 
Follicular and 
papillary thyroid 
17-67 Rodreigues-Serpa, 2003 
Liver 35-46 Finkelstein, 2003 
Skin >15 Hussein, 2002 
Gall bladder 35-65 Wistuba, 2001, 2002 
 
 
Table 3-2  
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 Another possibility is a mutation in the large non-coding exon accounting for the last 
1500 bp of the BAF155 mRNA.  Mutations within this region could result in significant 
changes in the tertiary structure of the mRNA leading to inefficient protein translation.  We 
are currently determining the sequence of this region to assess this prospect. 
 The importance of SKOV3’s lost leucine-zipper domain in BAF155 may be its ability 
to bind with other SWI/SNF complex members.  It is known that leucine zipper domains in 
general allow the proteins possessing them to dimerize, with themselves (homodimerize) or 
with other proteins possessing a leucine zipper domain (heterodimerize).  This has been 
suggested for BAF155 and BAF170.  Chen and Archer recently demonstrated another 
function for BAF155’s leucine zipper domain.  This domain was shown to be necessary for 
BAF155’s interaction with BAF57, stabilizing BAF57 in the cell.  In fact, similar functions 
have been shown for several of BAF155’s domains.  The SANT domain of BAF155 has been 
shown to be necessary for BRG1 binding and stabilization (Sohn, 2007) and BRM binding 
(Crosby, 1999).  The SWIRM domain of BAF155 was required for BAF60a and SNF5 
binding and stabilization (Sohn, 2007).   It has been proposed BAF155 is the scaffolding 
protein for the SWI/SNF complex, linking BRG1, and the therefore the remodeling 
capabilities of the complex, to the other subunits which interact with transcription factors or 
other targeting molecules.  SNF5 interacts with c-Myc to recruit SWI/SNF, GR with 
BAF60a, the HMG domain of BAF57 binds DNA, and BAF155 binds them all together with 
BRG1 to remodel chromatin.   To further the theory, reduced amounts of BRG1, SNF5, and 
BAF57 coincide with reduction, loss, or mutation of BAF155 (Chen, 2005; Sohn, 2007, 
DeCristofaro, 2001).  Our data would seem to refute this, as we show the presence of the 
other SWI/SNF members in cells with no detectable expression of BAF155 protein (Figure 
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3-1A).  The core complex also appeared to form in these cells lacking BAF155 (Figure 3-
5A).  If BAF155 was absolutely required as a scaffold for BRG1 and SNF5, as their only link 
to one another and the rest of the complex, we would not have been able to pull them down 
together in cells lacking BAF155 protein.   
 The apparent discrepancy may be explained by the following.  A truncated protein 
may not be detected in these cells due to the lack of the antibody binding site we used to 
detect BAF155 expression.  We have tested a recently released monoclonal antibody against 
BAF155 with a recognition site more central in the protein and still detect no protein in either 
cell line (data not shown) reference antibody.  This furthers the suspicion that no BAF155 
protein exists in these cell lines, although still not solving the conundrum of the complex 
forming in cells without a scaffold protein, if this is function of BAF155.  Another 
explanation may be that the job of scaffold protein is not solely that of BAF155.  There is 
significant sequence and domain homology among BAF155 and BAF170.  BAF170 may 
take over as scaffold in these cells, allowing the complex to form, although other more 
specific functions attributed to BAF155 are lost leading to the cancerous phenotype of these 
cells that we see reversed upon exongenous BAF155 expression (Figure 3-3C, D).  It is 
known that particular SWI/SNF members are vital to development (BRG1, SNF5, and 
BAF155) and others are dispensable (BRM) as demonstrated by the embryonic lethality of 
mice null for those subunits (Bultman,2000;  Roberts, 2000; Kim, 2001).  Many of the 
studies carried out to support the scaffold theory were done in immature cells, MEFs, 
developing thymocytes, or actively growing, transformed, immortalized cancer cell lines 
(Sohn, 2007, Chen, 2005).  It is possible BAF155 serves the purpose of scaffolding during 
development but may share this function with BAF170 upon cellular differentiation.   Further 
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characterization of BAF155 and BAF170 expression in developing or differentiating cells 
(such as the MEFs or developing thymocytes previously tested) would address these issues.     
 In conclusion, we submit an additional SWI/SNF core subunit, BAF155/SMARCC1 
as a likely tumor suppressor gene due to its loss in two carcinoma cancer cell lines including 
a hemizygous mutation, its genomic location in the tumor suppressor cluster region of 
chromosome 3p21 and because of its ability to cause a G0/G1 growth arrest in deficient 
cancer cell lines upon reexpression.  As mentioned earlier, BAF155 may be targeted as part 
of a tumor suppressor gene cluster on 3p21 to be epigenetically silenced, thereby affecting all 
SWI/SNF regulated genes, which are often cell cycle related.   The next step in the 
determination of potential effectors of BAF155 loss in cancer cells is exploration of 
epigenetic silencing mechanisms such as promoter hypermethylation, aberrant acetylation 
patterns, and myristoylation in normal developing cell lines such as MEFs or developing 
thymocytes known to have highly regulated BAF155, as well as in differentiated cells, cancer 
cells, and ‘normal’ cells such as normal human fibroblasts.  
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CHAPTER 4 
Inactivation of Tumor Suppressor of SNF5 Increases Loss of p53 
and Rhabdoid Tumor Formation in Snf5+/-;p53+/- Mice 
 
A. Abstract 
 Malignant rhabdoid tumors (MRTs), are highly undifferentiated pediatric cancers of 
unknown origin that arise in various anatomical locations with a very poor outcome.  The 
vast majority of these malignancies are caused by loss of the SNF5/INI1 component of the 
SWI/SNF complex.  However, the mechanism of tumor suppression associated with SNF5 
loss remains unclear.  SNF5’s loss demonstrated effects on the regulation of the activity of, 
cyclin D1, p16INK4A and pRb suggests a likely function through the SWI/SNF complex to 
affect transcription of several factors involved in cell cycle control.  However, previous 
studies in genetically engineered mouse (GEM) models have shown that loss of SNF5 on a 
p53 null background leads to 100% penetrance and significantly shorter latency periods of 
tumor development.  Here, we use established GEM models to further define the relationship 
between the SNF5 and p53 tumor suppressor pathways.  Combined haploinsufficiency in 
these mice also leads to decreased latency as well as increased penetrance of MRT formation, 
although MRTs do arise in alternate anatomical locations on the p53 heterozygous 
background.  Our studies suggest that loss of SNF5 activity changes the differentiation status 
of the p53 spectrum of tumors to those of MRTs.  They also raise the question whether SNF5 
loss accelerates p53 tumorigenesis as opposed to the opposite paradigm. 
B. Introduction 
 Although only representing a small percentage of pediatric neoplasms rhabdoid 
tumors are particularly devastating, killing the majority of affected children before their 
second birthday. These very aggressive tumors have been identified as rhabdoid or malignant 
rhabdoid tumors (MRTs) due to the morphological resemblance to rhabdomyoblasts (Haas, 
1981).  Historically considered a tumor of the kidney, extrarenal rhabdoid tumors are now 
recognized as typical MRTs as well, in as diverse locations as the liver, chest wall, and CNS 
(Gonzalez-Crussi, 1982; Lunch, 1983; Tsuneyoshi, 1985).   
 MRTs have always presented a diagnostic challenge given the largely 
undifferentiated although heterogeneous appearance, polyphenotypic immunoprofiles, and 
similarities to other tumor types.  The designation of rhabdoid historically relied on the 
histological appearance of large epithelioid cells with eccentric eosinophilic cytoplasm, 
vesicular nuclei, prominent nucleoli, and whorled bundles of intermediate filaments.  These 
characteristic rhabdoid cells, were not the typical cell in a malignant rhabdoid tumor, even 
rare in some tumors.  Therefore, false diagnosis was frequent, leading to unsuccessful 
treatments.  The discovery of deletions and mutations at 22q11.2 involving SNF5/INI1 has 
since facilitated diagnosis and treatment choices (Versteege, 1998; Biegel, 1999; Sevenet 
1999a&b; Rousseau-Merck, 1999).  SNF5 function is now recognized as being lost in almost 
100% of MRTs (Biegel, 2002).  The genetic mutation in MRTs is usually specific to SNF5, 
not chromosome- or genome-wide losses or instability, implying it is the specific loss of 
SNF5 that allows these tumors to form (Biegel, 1999).    
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 An array of mouse studies have followed the human analyses verifying SNF5’s 
specific role in tumor suppression.  SNF5 nullizygotes are embryonic lethal, dying at peri-
implantation stage, and conditional SNF5 null mutants lead to death within 3 weeks of SNF5 
loss due to hematopoietic failure.  A reversible conditional mutant that causes only partial 
penetrance of SNF5 loss was able to avoid the bone marrow failure and death experienced 
with the fully penetrant conditional mutation.  However, it showed a fully penetrant 
phenotype, developing CD8+ T cell lymphomas or MRTs by 11 weeks (Roberts, 2002).  The 
100% penetrance observed by 11 weeks of SNF5 loss brings SNF5 to the top of the list of 
deadly genetic mutations in cancer, as studied in mice.  Loss of either tumor suppressor gene 
p53, or p16INK4A leads to tumor development at median ages of 20 weeks and 38 weeks, 
respectively (Sharpless, 2001; Donehower, 1992).   
 Attention has turned to how SNF5 suppresses tumor formation, including its effects 
on known oncogenic signaling pathways.  Two groups showed that cyclin D1 absence allows 
SNF5+/- mice to survive tumor free, that primary mouse and human MRTs express cyclin 
D1 positive cells and that in some cases, several primary human rhabdoid tumors, but tumors 
lacking SNF5 inactivation, overexpressed cyclin D1 (Fujisawa, 2005; Tskitis, 2005).  These 
findings, as well as that of SNF5 protein’s interaction with c-Myc, Cyclin D1, and p21, 
suggest SNF5 tumor suppression abilities may function through manipulation of cell cycle 
pathways.  Guidi et al showed in 2006 that loss of the Rb pathway is epistatic to loss of SNF5 
in tumor formation.  More recently, a similar cross of mice haploinsufficient for SNF5 as 
well as losing the Rb family via cross with TgT121 mice (a truncated SV40 large T antigen 
that inactivates pRb and family members 107, and p130) have revealed a cooperation 
between SNF5 and the Rb family in tumor suppression as loss of both significantly 
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accelerates MRT formation (Chai, 2007).   Although every step involved in SNF5’s path to 
tumor suppression is not known, it seems fairly certain the Rb pathway is manipulated.   
 Aberrant proliferation can lead to Rb inactivation and subsequent apoptosis.  Several 
studies have demonstrated the p53 dependence of this process (Debbas, 1993; Lowe, 1994; 
Mecleod, 1996; Morgenbesser, 1994; Howes, 1994; Sabbatini, 1995; Wagner, 1994).  It 
seems apparent there are selective pressures to lose p53 for tumor survival and proliferation, 
demonstrated by Symonds et al 1994 where epithelial cell tumorigenesis occurs in response 
to pRb pathway inactivation, where normally Rb inactivation of the choroid plexus 
epithelium would result in p53-dependent apoptosis.  In fact, it is well documented that most 
human tumors harbor inactivation of Rb and p53 (Weinberg, 1995).  When considering the 
above evidence it becomes increasingly likely that loss of both p53 and Rb occur in many 
human neoplasms.  It was this suspicion that has lead Yaniv and colleagues to investigate the 
interaction of Snf5 and p53 tumor suppressors in rhabdoid tumorigenesis.  They 
demonstrated p53 nullizygosity indeed accelerated rhabdoid tumor formation in SNF5 
heterozygous mice – with complete penetrance within 19 weeks (from 28 weeks on wild type 
p53 background).  Neither the tumor spectrum, nor anatomical locations of the resultant 
rhabdoid tumors were altered (Klochendler-Yeivin, 2006).  This implies a true cooperation, 
not simply a combined effect, as all tumors were MRTs (SNF5-type tumors) in the same 
locations, with a much reduced latency and 100% penetrance, opposed to the no more than 
30% penetrance in Snf5+/- mice on a wild type p53 background (Roberts, 2000).   
 Although the above mentioned study, like the conditional Snf5 null mouse studies, are 
less likely to represent a true physiologic state, they do further the observation that combined 
p53 and Snf5 inactivation allows the propagation of increased numbers of MRTs.  Therefore, 
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to address this question in a more physiologically relevant genetically engineered mouse 
(GEM) model, we characterized tumor development in p53+/-, Snf5+/- and p53+/-,Snf5+/- mice.  
Our results reveal a cooperation between these two important tumor suppressor pathways 
may exist.   The cooperative effects of SNF5 and the p53 tumor suppressor pathways may 
extend beyond increasing MRT formation in general, with the p53 halploinsufficient 
background allowing MRT formation in alternate locations.  Alternatively, SNF5 loss may 
alter the differentiation status of existing p53-deficient tumors changing them into MRTs. 
 
C. Results 
1. SNF5 heterozygosity leads to increased penetrance and decreased latency of tumor 
formation on p53+/- background.   
 Previous studies have shown combined nullizygosity of SNF5 and p53 leads to 
increased tumor formation, but this occurs at a rate no longer compatible with life, with 
100% penetrance within 3 weeks (Roberts, 2005).  We crossed Snf5+/- females with p53+/- or 
p53+/- males to yield the Snf5+/-;p53+/- double heterozygous mice, as well as control 
genotypes: Snf5+/-;p53+/+, Snf5+/+;p53+/+, and Snf5+/+,p53+/- (see Materials and Methods for 
background strain and origin of mice).  The overall survival of these genotypes can be seen 
in Figure 4-1.  In the p53 heterozygote mice, we observe the expected >50% penetrance and 
14.5 month tumor onset similar to that observed in previous p53+/- mouse studies 
(Donehower, 1992; Jacks,1994) .  Approximately 40% of SNF5+/- mice form rhabdoid 
tumors at a median age of 15 months.  While this penetrance is slightly higher than that 
reported in the original Snf5 mouse studies published by Roberts in 2000, additional 
malignancies and pathologies were acknowledged after publication (personal 
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communication) that would rise to the level of penetrance we see here.  The mice 
heterozygous for both p53 and Snf5 however, have a median age of tumor formation of only 
9.5 months, and a total penetrance of over 85%.    This increase in tumor penetrance in the 
double heterozygous mice appears to be more than an additive effect.  Figure 4-1B displays 
only rhabdoid tumor formation in Snf5+/- p53+/+  mice and Snf5+/- p53+/- mice, which reveals a 
decrease in latency of rhabdoid tumors in the double heterozygotes.  The reduction in latency 
of the double heterozygote rhabdoid tumors is largely responsible for the overall reduction in 
latency of rhabdoid tumors in all mouse groups. 
  
2. Snf5+/-;p53+/- mice develop MRTs, lymphomas, and osteosarcomas 
As shown by Donehower in 1992 and Harvey in 1993, p53 heterozygous mice are 
predisposed to lymphomas  (~30%), osteosarcomas(~60%), and some soft-tissue sarcomas 
and carcinomas as well, at a rate of 50% by 18 months.  Just under half of Snf5+/- mice, form 
malignant rhabdoid tumors of the soft tissue of the head and neck, as well as CNS (Roberts, 
2000 and personal communication).  Snf5 null conditional knockout mice formed lymphomas 
exclusively within 3 weeks (Roberts, 2002).  We observed an >80% penetrance of rhabdoids, 
osteosarcomas, and lymphomas in the Snf5+/-;p53+/- mice.  It is of note, that the penetrance of 
facial and CNS MRTs usually observed in Snf5+/- on a wild type p53 background was not 
increased in these Snf5+/- mice on a p53+/- background.  A small percentage of the total 
rhabdoid tumors from the double heterozygous group were histologically rhabdoid but 
presented at alternate locations to the expected soft tissues of the face.  No tumors completely 
novel to either genotype were observed.  
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Figure 4-1: Survival of eouble heterozygous mice 
 
(A) Overall survival of Snf5+/-, p53+/-, and Snf5+/-; p53+/- mice in the study   
 
(B) Rhabdoid incidence only in double heterozygote mice and Snf5+/- mice.  Mice were 
sacrificed when an obvious tumor or paralysis was noticed.  Healthy mice at 25 months were 
sacrificed and recorded as non-events.   N values are noted on the figure.   Wild type 
littermates experienced 100% survival at 25 months are not included on this survival curve. 
 93
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4-1 
0.0
0.1
0.2
0.3
0.4
0.5
0.6
0.7
0.8
0.9
1.0
S
ur
vi
vi
ng
0 5 10 15 20
A 
 
Age at Death (months)Months to tumor onset 
0.0
0.1
0.2
0.3
0.4
0.5
0.6
0.7
0.8
0.9
1.0
S
ur
vi
vi
ng
2 4 6 8 10 12 14 16 18
months to tumor onset
 
B 
 94SNF5+/-       (n =10) 
p53+/-       ( n=15) SNF5+/- p53+/-       (n= 43)25
SNF5+/-     (n = 7) (n=11)   SNF5+/- p53+/-20 22
3. LOH of SNF5 and p53 occurs in osteosarcomas and variably in lymphomas of double 
heterozygous mice, but without an increase in penetrance.   
 As shown in Roberts et al 2005, Snf5 nullizygosity can lead to early lymphomas.  
Lymphomas are common as well in p53 +/- mice, displaying up to 50% p53 LOH in those 
tumors.  It would not have been surprising to observe an increase in lymphomas here. 
This is not what we observed.  While the overall survival and tumor formation was affected, 
it was not due to increased lymphoma or osteosarcoma formation.  The previously observed 
LOH rates are maintained here as well, with the majority lymphomas and osteosarcomas 
losing p53 heterozygosity.  Interestingly, no osteosarcomas formed in the double 
heterozygote mice that displayed p53 expression by IHC (sample staining in Figure 4-2C)  
and this was the only tumor type that 100% of the type lost expression of both Snf5 (by PCR) 
and p53 (by IHC).   The age of onset, of these osteosarcomas was not extreme nor out of the 
normal latency range (table 4-1).    
 
4. Immunoprofile of mouse rhabdoid tumors recapitulates that of human rhabdoid 
tumors.  
  One question about the validity of GEM models for human cancers is how accurately 
they embody the features of their representative human malignancy.  The haploinsufficient 
Snf5 mouse has been well characterized as producing MRTs with histologies similar to those 
observed in humans.  We also examined a limited number of immunohistochemical markers to 
determine whether the MRTs in the Snf5+/- mice showed a similar pattern to their human 
counterparts.  We also looked at the immunoprofile in a representative set of MRTs from the 
Snf5+/-;p53+/- mice to assess whether loss of p53  
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Table 4-1: Summary of Snf5 and p53 loss of heterozygosity in the tumors observed in the 
double heterozygotes as well as the two control genotypes.  
 
Tumors were removed at necropsy and flash-frozen at necropsy for subsequent DNA 
extraction.   LOH was determined by PCR.  Not all tumors were able to be tested, 
percentages given are of the tumors able to be genotyped by PCR. 
 
 96
  
        
 
 
 
 
 
 
 
Mouse Genotype & tumor type p53 LOH Snf5 LOH 
 Snf5+/- p53+/+                   Rhabdoids Not tested 3 of 4 (75%) 
Snf5+/+ p53+/-             Lymphomas + 
Osteosarcomas
4 of 4 (100%) not tested 
Snf5+/- p53+/-                    Rhabdoids 1 of 5 (20%) 7 of 8 (88%) 
Snf5+/- p53+/-           Non-Rhabdoids 2 of 3 (67%) 3 of 4 (75%) 
 
 
  
Table 4-1 
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Figure 4-2: LOH determination of rhabdoid tumors formed in double heterozygote mice 
 
(A) Representative loss of heterozygosity determination by PCR.  Tumor samples were 
flash-frozen immediately at necropsy for subsequent DNA extraction and LOH 
determination. 
 
(B) Representative image of SNF5 western blot used to determine SNF5 and p53 LOH.  
Protein was extracted from tumor tissue flash-frozen at necropsy.  30ug of protein 
was loaded into each well. 
 
(C) Representative average signal strengths assigned to tumors immunohistochemically 
stained for p53.  These average signal strengths were multiplied by the percentage of 
positive tumor cells in the core for a single number score for each core scored.  These 
numbers were averaged and are summarized on table 4-2 
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function affected the phenotype of these tumors.  Finally, we determined the origin of the 
lymphomas in the p53+/- and Snf5+/-;p53+/- mice to ascertain if the loss of both tumor 
suppressor genes affected the origin of these hematopoietic tumors. 
 Approximately 90% of the MRTs, from either genotype, were positive for S100ß 
expression, similar to our previous report (Chai, 2007) (Table 4-2, figure 4-3).  We also 
observed expression of vimentin, an intermediate filament found in cells of mesenchymal 
origin, in all MRTs (Table 4-2, Figure 4-3).   The staining of lymphomas from the Snf5+/- 
mice as well as the double heterozygotes are suspected to be mature T-cell lymphomas, as 
they did not express the B-cell marker B220.  Staining for the T-cell marker CD3 will verify 
these are mature T-cell lymphomas.  While the majority of the lymphomas in the Snf5+/-
;p53+/- mice are likely of T-cell origin, we found one B-cell lymphoma.    
 
D. Discussion 
 A few decades have passed since the formal recognition and diagnosis of MRT came 
to exist (Beckwith, 1978; Haas, 1981; Rorke, 1996).  While we have determined the 
underlying genetic causal relationship of Snf5 loss with MRT formation, it has yet to change 
the prognosis of infants diagnosed with this devastating aggressive neoplasm.  
 Given the difficulty in studying the molecular mechanisms of human cancers, the 
genetically engineered mouse model has been invaluable for providing needed insights into 
this important problem.  However, it has been difficult to find a GEM for MRT because Snf5 
loss  
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Table 4-2:  Results of immunohistochemistry scoring of p53, S100β, Vimentin, and B220 
(for lymphomas).  Results are grouped according to genotype of the mouse 
  
(A) p53+/- Snf5+/+ mice 
 
 (B) Snf5+/- p53+/+ mice  
 
(C) wild type controls  
 
(D) Snf5+/- p53+/- mice 
 
Each core, once stained, was scored for average signal strength of positive tumor cells and 
for percentage of tumor cells demonstrating some positivity.  These two values were 
multiplied for each score and averaged for the total number of scores.  There were three cores 
of most samples on each array and two array slides stained, so the majority are an average of 
6 scores.  Ncp = no core present to score.    n/a = core was not scored due to lack of a core 
present on the array or the stain was not relevant to that tumor (B220 only relevant for 
lymphomas) 
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A 
Mouse 
# 
Age in 
months at 
tumor 
onset Histologic diagnosis 
average 
p53 
average 
S100β 
average 
Vimentin 
average 
B220 
130 11.5 Lymphoma 1 120 144 0 
113 12.5 Lymphoma 0 2 73 19 
103 14 Lymphoma 4 3 100 80 
144 14 Lymphoma 95 11 13 1 
133 11.5 Osteosarcoma 0 125 180 N/A 
B19 15.25 Osteosarcoma 0 52 153 N/A 
1401 17.5 Osteosarcoma 0 63 188 N/A 
                 
B mouse 
# 
age at 
tumor 
onset (mo) Histologic diagnosis 
average 
p53 
average 
S100β 
average 
Vimentin 
average 
B220 
B47 9 Rhabdoid 0 2 100 N/A 
B73 10 Rhabdoid 53 92 65 N/A 
B29 16 Rhabdoid 30 127 93 N/A 
B56 17 Rhabdoid 1 5 15 N/A 
B27 20 Rhabdoid 50 122 180 N/A 
 
C 
mouse 
# 
age at 
tumor 
onset (mo) Histologic diagnosis 
average 
p53 
average 
S100β 
average 
Vimentin 
average 
B220 
wt 1   normal thymus n/a n/a 115 n/a 
wt 1   normal spleen n/a 7 77 40 
 
Table 4-2 (continued on next page) 
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D 
mouse 
# 
age at 
tumor 
onset (mo) Histologic diagnosis 
average 
p53 
average 
S100β 
average 
Vimentin 
average 
B220 
114 2 Lymphoma 90 ncp ncp ncp 
1407 6.2 Lymphoma 0 2 95 62 
106 13 Lymphoma 0 133 50 2 
146 16 Lymphoma 2 10 163 N/A 
111 12.5 Osteosarcoma 0 63 112 N/A 
146 16 Osteosarcoma 0 10 148 N/A 
72 4 Rhabdoid 0 110 193 N/A 
141 5.5 Rhabdoid 0 10 180 N/A 
1507 6.5 Rhabdoid 0 30 160 N/A 
151 7.5 Rhabdoid 0 100 140 N/A 
86 8.3 Rhabdoid 3 73 118 N/A 
161 9 Rhabdoid 0 40 192 N/A 
B34 12.5 Rhabdoid 20 80 70 N/A 
85 13 Rhabdoid 0 78 121 N/A 
93 13 Rhabdoid 0 78 112 N/A 
81 14 Rhabdoid 60 80 149 N/A 
143 16 Rhabdoid 1 38 186 N/A 
1400 17 Rhabdoid 13 116 187 N/A 
B42 17 Rhabdoid 0 145 138 N/A 
 
 
Table 4-2 
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Figure 4-3:  Representative immunohistochemical staining of mouse tumor tissue microarray 
assigned scores of low (1+) and high (2+ or 3+) average signal strengths  Results are 
summarized on Table 4-2 
 
B220 (A, B) 
 
S100β (C, D) 
 
Vimentin (E, F)  
 
  
 104
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
FIGURE 4-3 
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results in embryonic lethality and Snf5 heterozygosity leads to histologically 
indistinguishable MRT but at a low penetrance with an extended latency.  Complicating 
matters for conditional deletion studies, the cell of origin for MRTs remains unknown. 
 Despite these problems, we have gained invaluable information from GEM involving 
Snf5 deletion.  Multiple mouse studies have revealed cooperation between SNF5 and other 
tumor suppressors in the prevention of MRTs.  Guidi et al, (2006) has demonstrated Snf5 
loss may be epistatic to Rb loss, but a more recent study demonstrates loss of the entire Rb 
family accelerates MRT development (Chai, 2007).  This would imply that SNF5 tumor 
suppression may involve the Rb pathway but clues to SNF5 mechanism of tumor suppression 
does not end with Rb.  These data seem to fit with the etiology of human disease where 
MRTs do not appear to lose Rb or p16INK4A function. 
 Loss of SNF5 function on a p53 null background in GEM led to 100% tumor 
penetrance within 19 weeks (Klochendler-Yeivin, 2006).  This group also showed an 
accumulation of p53 in SNF5 deficient cells in culture displaying growth defects followed by 
apoptosis.  In contrast, the SNF5 deficient cells on the p53-null background showed a 
reduced level of apoptosis.  Therefore, one could attribute the increased tumor incidence in 
the Snf5+/-;p53+/- mice to a reduced rate of apoptosis associated with the p53 null background.   
 In the current mouse model, cells could lose either one or both of these tumor 
suppressor pathways in order to progress to tumorigenicity.  In the case of the facial MRTs 
that presumably correspond to those found in the Snf5+/- mice, we did not observe an increase 
in penetrance.  However, an apparent decrease in latency for the appearance of these tumors 
compared to the Snf5 heterozygous mice on a p53 wild type background (Figure 4-1).  A low 
frequency of LOH for p53 in these tumors suggesting that p53 haploinsufficiency alone 
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could accelerate SNF5 tumorigenesis in these mice.  We did observe an increase in the 
penetrance of the spinal cord tumors in the Snf5+/-;p53+/- mice reminiscent of what we found 
in the TgT121; Snf5+/- mice (Chai 2007).  However, sufficient material was not obtained to 
carry out LOH analyses on these tumors.  Therefore, we do not know if increase in the 
frequency of these MRTs was due to p53 LOH or for other reasons.  It is of note, that not 
only was p53 loss of expression observed by IHC in the osteosarcomas formed in the double 
heterozygotes, but Snf5 LOH was selected for as well, but without an observed change in 
latency, penetrance, or histologic appearance.  This may mean that loss of SNF5 was 
incidental and perhaps late in the progression of the tumor so the Snf5 characteristic rhabdoid 
cell phenotype did not manifest.   
 In contrast, we found a high frequency of LOH for both Snf5 and p53 in the non-
MRTs from the Snf5+/-;p53+/- mice (Table 4-1).  The frequency of p53 LOH was remarkably 
similar to that observed in the p53+/- mice alone.  Again, a decrease in latency was observed 
for the development of these tumors when compared to the p53 heterozygous mice.  The fact 
that p53 LOH occurred in both mouse models implies that the loss of remaining wild-type 
Snf5 allele led to the acceleration of tumor formation in these mice.  
 Several possibilities may explain the observed increase in tumor formation with the 
combined haploinsufficiency of p53 and Snf5.  First, Vries et al demonstrated in their 2005 
study that 10% of MRT cell lines are near tetraploid and over half of the MRT cell lines bear 
chromosomal aberrations.  They went on to show these aberrations can be corrected in the 
cell population by addition of SNF5 which leads the genetically unstable cells to senesce.  
Therefore, SNF5 haploinsufficient mice may experience substantial genomic instability 
leading to secondary genetic events such as loss of p53 activity.  This model could account 
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for the acceleration of development of non-MRTs in Snf5+/-;p53+/- mice.  However, 
molecular and cytogenetic studies of human MRTs suggest that genomic instability occurs 
infrequently, with chromosomal aberrations localized mainly to region surrounding the SNF5 
gene (Biegel, 1999).  Thus, this may not provide the most likely mechanism. 
 A second explanation for the increase in tumor formation in the double heterozygous 
mice is that p53 null cells allow genetic instablity, increasing the frequency of Snf5 LOH.   
This scenario also appears unlikely since previous studies in GEM models suggest that loss 
of p53 function does not lead directly to global chromosomal instability (Lu, 2001).  
Furthermore, loss of p53 is not been found in the primary MRTs of children presenting with 
this disease (Dr. Jaclyn Biegel, personal communication).  In fact, these tumors respond well 
to chemotherapy and radiation and are frequently ablated.   Unfortunately, MRTs can return 
months to years later in a chemotherapy-resistant form in which the p53 status has not been 
established.   
 We favor a third explanation for observations in human MRT development as well as 
the increase in MRTs in the double heterozygous mice.  Snf5 LOH is likely occurring in the 
Snf5+/-;p53+/- mice at an equivalent rate and locations as it does in the p53+/+ mice.  However, 
on a p53 wild type background, these Snf5 null cells are arrested or undergo apoptosis via 
induction of p21 and subsequent halting cell cycle progression via Rb.  On the p53+/- 
background, most cells possess enough functional p53 still exists to eliminate themselves if 
they lose SNF5 function.  However, a few cells are able to escape apoptosis due to low p53 
levels causing a slight increase in tumor formation.   Since tumors developing from Snf5 loss 
have a shorter latency than p53 (as determined in previous mouse studies), you would expect 
to see more of an increase in SNF5-type tumors (MRTs) and little or no increase in tumor 
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types associated with p53 LOH (lymphomas and osteosarcomas).  This is precisely what we 
observed in this study.  This has also been posed by Yaniv and colleagues, that loss of p53 
could be accelerating the LOH of Snf5 in certain populations and then may be allowing or 
even enhancing the survival of these Snf5-/- cells to form MRTs (Klonchendler-Yeivin, 
2006).   
 In this study the combined loss of Snf5 and p53 revealed a cooperation between the 
two tumor suppressors yielding reduced latency and increased penetrance of rhabdoid 
tumors.  The increase in rhabdoids observed were not simply an increase in expected MRTs, 
but there were a subset of p53-/-  tumors with a histologic rhabdoid appearance.  We believe it 
is the loss of Snf5 that made the neoplasm histologically rhabdoid (verified by the distinctive 
rhabdoid features seen by H&E and the IHC profile matching that of human MRTs (Figure 
4-3) even though progression of the tumor may have been afforded by p53 inactivation.  It 
seems that given the Snf5 haploinsufficient status of the mice, haploinsufficiency of p53 was 
sufficient to allow a larger number of rhabdoid tumors to progress to frank, solid tumors.    
  Given the extensive loss of p53 in human tumors and the chemotherapy resistance of 
secondary rhabdoid tumors in humans, this study may lead to a deeper understanding of the 
mechanism of SNF5 tumor suppression and MRT behavior, specifically CNS MRTs, now 
considered typical MRTs, may be due to p53 inactivation as well, noting the role of p53 in 
survival and death checkpoints in the central nervous system neurons (Aloyz, 1998; Xiang, 
1996).   Further insight into the relationship of essential tumor suppressors like SNF5 will 
inevitably allow for more successful treatment avenues for devastating childhood neoplasms 
like MRT.    
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CHAPTER 5 
 
SUMMARY AND PERSPECTIVES 
 
A. Summary 
 The status of the SWI/SNF chromatin remodeling complex’s role in effecting the 
transcription of only 5% of the genome may underestimate the overall effects of its activity.  
It is likely to affect far more than 5% of the genome considering the profiles of the genes that 
fall into that 5%, their associations, and their effects on cell cycle.  Solid links have been 
established between SWI/SNF subunits, cell cycle control, and often tumorigenesis, via 
specific complex members.  SNF5 is one such member, a bone fide tumor suppressor gene, it 
is also vital to development.  The mechanism in which SNF5 operates to affect cell cycle and 
tumorigenesis, and any associations necessary for this pathway have not been fully defined.  
This is also true of core member BAF155, which is minimally characterized at this point.  
Although known to be essential to development like other SWI/SNF core members, 
BAF155’s role in tumor suppression is largely unknown.  Given it’s role as a necessary core 
member in a complex whose role involves the transcriptional regulation of genes important 
to cell cycle control, it is also likely BAF155 has tumor suppressive effects.    
 In addressing these questions, I sought to further characterize the tumor suppressive 
capabilities of two of SWI/SNF’s core members, SNF5 and BAF155, in two aims.  The first 
aim tests BAF155’s potential tumor suppressive capabilities with specific standard tests of 
growth suppressive effects in cell culture.  Specifically, exploring any growth control effects 
exerted upon expression of BAF155 in tumor cell lines lacking endogenous expression.  The 
second aim sought to further define the mechanism of SNF5’s tumor suppression.  
Specifically, I sought to determine any cooperativity that may exist between the SNF5 and 
the established cell cycle control pathway, p53.  The results of these studies lead me to 
conclude the following:     
• Loss of BAF155 occurs in carcinoma cell lines.   Complete loss of protein expression 
was observed in two carcinoma cell lines, SKOV3 (ovarian carcinoma) and SNUC2B, 
colorectal carcinoma).  This loss was limited to the expression of protein because northern 
blots revealed full length BAF155 message in both cell lines.  Loss may be due, at least in 
SKOV3, to a truncating mutation and an 855AA protein lacking its leucine-zipper domain.   
• Loss of BAF155 is not due to protein degradation.  Loss of this subunit is not due to 
aberrant degradation by the ubiquitin-proteasome pathway because when this pathway was 
interrupted, no accumulation of BAF155 was detected in these cells.   
• BAF155 leads to reduction in growth due to induced senescence upon re-expression 
in cells lacking endogenous BAF155 expression.  The reduction in colony forming ability 
observed upon re-expression of full length BAF155 did not occur upon transfection with a 
truncation mutant of BAF155, suggesting the need for full length BAF155 for this effect.   
• BAF155’s growth suppressive capabilities are dependent on its leucine-zipper and /or 
proline-glutamine rich domains.  The truncation mutant that was unable to induce a growth 
arrest lacked the c-terminal leucine zipper and proline-glutamine rich domains.   
• BAF155 is not required for RB-mediated cell cycle arrest.   Upon expression of 
p16INK4A, to induce a Rb-mediated cell cycle arrest, the BAF155 null cells arrested in G0.  
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BrdU assays showed a lack of cells entering S phase, and flow cytometry verified a G0/G1 
arrest.   
• Cooperativitiy exists between the tumor suppressive pathways of SNF5 and p53.  The 
Snf5+/-;p53+/- mice developed tumors at median age of 9.5 months, as opposed to 15 and 17 
months in their single mutant Snf5+/- or p53+/- control genotype littermates, respectively.   
• Snf5 and p53 cooperate to suppress MRT formation in the mouse.  The increase in 
penetrance of tumor formation in the double heterozygotes can be attributed to an increased 
numbers of malignant rhabdoid tumors.  There were a subset of MRTs with a loss of 
heterozygosity of p53, accounting for a subset of the additional rhabdoids seen in the double 
heterozygotes .  An increase in penetrance of lymphomas or osteosarcomas was not seen, nor 
were any novel tumor types observed. 
• The immunoprofile of mouse rhabdoid tumors recapitulates that of human MRTs.  
Immunohistochemical staining of several rhabdoids for vimentin and S100ß revealed the 
same staining patterns seen in human MRTs.  The mouse MRTs express vimentin invariably 
and S100ß to varying degrees. 
 
B. Perspectives 
 The field of molecular cancer genetics is currently at the doorway of a new way of 
looking at tumor causation, with the onslaught of information describing epigenetic gene 
silencing in cancer flooding the literature.   The perfect example is that of the RB /E2F 
pathway, specifically p16INK4A and its involvement in cell cycle control.  p16INK4A is the 
poster-protein for epigenetic silencing, as one of the more important genes to be well 
characterized as being silenced due to hypermethylation.  Increasingly more cancer 
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phenotypes are attributed to some epigenetic cause, much more so than simple somatic 
genetic mutations.  Large regions of the human genome may contain a cluster of tumor 
suppressor genes, such as chromosome 3p21, where few somatic mutations are found but 
many genes related to cell cycle control, differentiation, and proliferation, are epigenetically 
silenced (see discussion in chapter 3 and Ji, 2005).  These new discoveries continue to add to 
the complexity of a disease already appearing infinitely complex.    
 The SWI/SNF complex is the epitome of the intricacy of cancer causation, as it is 
involved in gene transcription directly, albeit by independent targeting.  As we find that the 
loss of more specific subunits correlate with specific cancer phenotypes, we are also realizing 
the mechanism involved appears to be more epigenetic than genetic.  
  Despite the compounding complexity of cancer, I believe the simplest answer to 
questions like the causation of rhabdoid tumorigenesis is still the best.  Knudsen’s two hit 
hypothesis is generally connoted with the accumulation of genetic lesions.  It seems more 
precise now to think of the two required hits as being hits to mechanisms, or pathways more 
than single coding region mutations or losses.  For example, the inability to successfully treat 
recurrent rhabdoids in children successfully treated with chemotherapy of the original 
rhabdoid and the appearance of non-renal, non-CNS rhabdoid tumor formation in adults may 
be due to loss of an additional tumor suppressing pathway.  Loss of p53 or some other 
mechanism or pathway, the second hit required, may be what is causing the alternate location 
rhabdoids in humans and mice, as well as the chemotherapy -resistance of the recurrent 
rhabdoids in children.  It would follow that the first, apparently successful round of 
chemotherapy or radiation selected for the tumor cells that could by-pass this second 
pathway.   This second pathway, perhaps p53, may be what allows the development of SNF5 
 117
null cells to malignant rhabdoid tumors in the alternate location and that this usually occurs 
later in life.  Preliminary indications are that p53 loss of heterozygosity is found only in the 
alternate location MRTs in the mice in this study. 
 A loss of Snf5 heterozygosity along with p53 loss of expression was observed in both 
of the only 2 osteosarcomas developed in the double heterozygotes.   This was the only 
tumor type observed to lose Snf5 heterozygosity and not appear histologically as a rhabdoid 
or a lymphoma.  An opposing mechanism may have lead to the development or progression 
of the osteosarcomas than was observed in the rhabdoids developed in the double 
heterozygotes.  Or perhaps, as with the rhabdoids, loss of p53 occurred as usual in these 
tumors and, given the speed and aggressive nature of these tumors, it may be likely some 
genetic instability occurred leading indirectly to Snf5 loss.  Therefore Snf5 loss was 
incidental, and perhaps late in the progression of the osteosarcoma, as no other sign of Snf5 
LOH was observed, such as the histologic rhabdoid cell type.   
 The other core member that was the focus of this study is also likely to involve 
several pathways in its proper functioning.  Several functions have been proposed for nearly 
every domain of BAF155 from transcriptional control to protein-protein interactions to self-
dimerization.   It has been proposed BAF155 is the scaffolding protein for the SWI/SNF 
complex, as it has been shown to bind specifically to several other SWI/SNF subunits and 
this binding is necessary and sufficient for the stabilization and nuclear localization of those 
other subunits.  This directly implicates BAF155 in the regulator of the steady state levels of 
the other SWI/SNF subunits and arguably the entire complex.  BAF155 does not seem to be 
affected by the proteasomal degradation that befalls other SWI/SNF subunits not properly 
bound to BAF155.  It begs the question, what mechanism controls the steady state levels of 
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BAF155?  The recent studies would imply that he who controls BAF155, controls the 
SWI/SNF complex entire.  I find this conclusion questionable given the presence and 
associations of SWI/SNF core members in our cell lines lacking BAF155 expression.  Either 
this is not the case, that BAF155 is a scaffold for SWI/SNF, or the mechanism is overridden 
in these cells, perhaps part of a larger loss of mechanism leading to their cancerous 
phenotype.  However, we show re-expression of full-length wild type BAF155 is sufficient to 
cause a G0/G1 growth arrest due to senescence, and this response is specific to full length 
wild type BAF155, as a truncation mutant BAF155 does not accomplish arrest.   
 Previous studies have demonstrated LOH and chromosomal abnormalities in 
numerous cancer types (shown in Table 3-1) and as a marker of poor prognosis in the 
metastasis of neuroblastoma in the specific area of chromosome 3 where the BAF155 gene 
resides, 3p21 (Busson, 2004; Kuroki T, 2005; Mitelman, 1997; Todd, 1996; Killary, 1992; Cheng, 
1998; Braga, 1999).   Therefore, evidence of a role for BAF155 in the regulation of the cell 
cycle control makes it another candidate tumor suppressor gene from this region.   It has been 
proposed that this region of chromosome 3, 3p21, houses a tumor suppressor gene cluster of 
several identified and unidentified tumor suppressor genes important in the suppression of 
carcinomas specifically (Ji, 2005).    
 
 119
Literature Cited 
Acevedo, C. M., M. Henriquez, et al. (2002). "Loss of heterozygosity on chromosome arms 
3p and 6q in microdissected adenocarcinomas of the uterine cervix and adenocarcinoma 
in situ." Cancer 94(3): 793-802. 
 
Ae, K., N. Kobayashi, et al. (2002). "Chromatin remodeling factor encoded by ini1 induced 
G1 arrest and apoptosis in ini1-deficient cells." Oncogene 21: 3112-20. 
 
Aloyz, R., S. Bamji, et al. (1998). "p53 is essential for developmental neuron death as 
regulated by the TrkA and p75 neurotrophin receoptors." J Cell Biology 143: 1691-
1703. 
 
Amati, B., S. Rank, et al. (2001). "Function of the c-Myc oncoprotein in chromatin 
remodeling and transcription." Biochem Biophys Acta 1471: M135-45. 
 
Ashwell, J. D., F. W. Lu, et al. (2000). "Glucocorticoids in T cell development and function" 
Annu Rev Immunol 18: 309-45. 
 
Bates, S. and K. Vousden (1996). "p53 in signalling checkpoint arrest or apoptosis." Curr. 
Opin. Genet. Dev 6: 12-19. 
 
Beckwith, J. and N. Palmer (1978). "Histopathology and prognosis of Wilm's tumor: Results 
form the First National Wilm's Tumor Study." Cancer 41: 1937-48. 
 
Beier, R., A. Burgin, et al. (2000). "Induction of cyclin E-dck2 kinase activity, E2F-
dependent transcription and cell growth by Myc are genetically separable events." 
EMBO J 19: 5813-5823. 
 
Belinsky, S. (2004). "Gene-promoter hypermentylation as a biomarker in lung cancer." Nat 
Rev Cancer 4: 707-17. 
 
Belinsky, S., K. Nikula, et al. (1998). "Aberrant methylation of p16(INK4A) is an early event 
in lung cancer and a potential biomarker for early diagnosis." Proc Natl Acad Sci U S A 
95: 11891-11896. 
 
Bestor, T. (1998). "The host defence function of genomic methylation patterns." Naovartis 
Found. Symp. 214: 187-199 228-232. 
 
Betz, B., D. Strobeck, et al. (2002). "Re-expression of hSNF5/INI1/BAF47 in pediatric tumor 
cells leads to G1 arrest associated with induction of p16ink4A and activation of RB." 
Oncogene 21: 5193-203. 
 
Biegel, J., C. Allen, et al. (1996). "Narrowing the critical region for a rhabdoid tumor locus in 
22q11." Genes Chromosomes Cancer 16(94-105). 
 
 120
Biegel, J., B. Fogelgren, et al. (2000). "Mutations of the INI1 rhabdoid tumor suppressor 
gene in medulloblastomas and primitive neuroectodermal tumors of the central nervous 
system." Clin Cancer Res 6(2759-63). 
 
Biegel, J., G. V. Kalpana, et al. (2002). "The role of INI1 and the SWI/SNF complex in the 
development of rhabdoid tumors." Cancer Research 61(1): 323-328. 
 
Biegel, J., L. Rorke, et al. (1990). "Monosomy 22 in rhabdoid or atypical tumors of the 
brain." J Neurosurgery 73: 710-714. 
 
Bochar, D., L. Wang, et al. (2000). "BRCA1 is associated with a human SWI/SNF-related 
complex: linking chromatin remodeling to breast cancer." Cell 102(257-65). 
 
Braga, E., E. Pugacheva, et al. (1999). "Comparative allelotyping of the short arm of human 
chromosome 3 in epithelial tumors of four different types." FEBS Lett 454(3): 215-9. 
 
Braga, E. A., V. I. Kashuba, et al. (2003). "New tumor suppressor genes in hot spots of 
human chromosome 3: new methods of identification." Mol Biol  37(2): 194-211. 
 
Bultman, S., T. Gebuhr, et al. (2000). "A Brg1 null mutation in the mouse reveals functional 
differences among mammalian SWI/SNF complexes." Molecular Cell 6: 1287-1295. 
 
Busson, M., S. Romana, et al. (2004). "Cryptic translocations involving chromosome 20 in 
polycythemia vera." Ann Genet 47(4): 365-71. 
 
Chai, J., A. Char boneau, et al. (2005). "Loss of the hSNF5 gene comcomitantly inactivates 
p21CIP/WAF1 and p16INK4A activity associated with replicative senescence in A204 
rhabdoid tumor cells." Cancer Res 65(22): 10192-10198. 
 
Chai, J., X. Lu, et al. (2007). "Tumor-specific cooperation of retinoblastoma protein family 
and Snf5 inactivation." Cancer Res 67(7): 3002-9. 
 
Chakraborty, S. B., S. Dasgupta, et al. (2003). "Differential deletions in 3p are associated 
with the development of head and neck squamous cell carcinoma in Indian patients." 
Cancer Genet Cytogenet 146(2): 130-8. 
 
Chen, J. and T. Archer (2005). "Regulating SWI/SNF subunit levels via protein-protein 
interactions and proteasomal degradation: BAF155 and BAF170 limit expression of 
BAF57." Mol Cell Biol 25(20): 9016-9027. 
 
Chen, W., T. Cooper, et al. (2004). "Epigenetic and genetic loss of Hic1 function accentuates 
the role of p53 in  tumorigenesis." Cancer Cell 6: 387-98. 
 
Cheng, S., K. Davies, et al. (1999). "c-MYC interacts with INI1/SNF5 and  requires the 
SWI/SNF complex for transactivation function." Nat Genet 22: 102-5. 
 
 121
Chi, T., M. Wan, et al. (2003). "Sequential roles of Brg, the ATPase subunit of BAF 
chromatin remodeling complexes, in thymocyte development." Immunity 19: 169-82. 
 
Chino, K., M. Esumi, et al. (1999). "Characteristic loss of heterozygosity in chromosome 3P 
and low frequency of replication errors in sporadic renal cell carcinoma." J Urol 162(2): 
614-8. 
 
Crosby, M. A., C. Miller, et al. (1999). "The trithorax group gene moira encodes a brahma-
associated putative chromatin-remodeling factor in Drosophila melanogaster." Mol Cell 
Biol 19(2): 1159-70. 
 
Debbas, M. and E. White (1993). "Wild-type p53 mediates apoptosis E1A, which is inhibited 
by E1B." Genes and Development 7: 546-554. 
 
DeCristofaro, M., B. Betz, et al. (2001). "Characterization of SWI/SNF protein exression in 
human breast cancer cell lines and other malignancies." J.Cell Physiology 186: 136-
145. 
 
DeCristofaro, M., B. Betz, et al. (1999). "Alteration of hSNF5/INI1/BAF47detected in 
rhabdoid cell lines na dprimary rhabdomyosarcomas but not Wilms' tumors." Oncogene 
18: 7559-7565. 
 
Dellas, A., J. Torhorst, et al. (1999). "Prognostic value of genomic alterations in invasive 
cervical squamous cell carcinoma of clinical stage IB detected by comparative genomic 
hybridization." Cancer Res 59(14): 3475-9. 
 
Dhalluin, C., J. E. Carlson, et al. (1999). "Structure and ligand of a histone acetyltransferase 
bromodomain." Nature 399(6735): 491-6. 
 
Donehower, L. (1992). "Mice deficient for p53 are developmentally normal butsusceptible to 
spontaneous tumours." Nature 356: 215-221. 
 
Douglass, E., M. Valentine, et al. (1990). "Malignant rhabdoid tumor: a highly malignant 
chilhood tumor with minimal karyotypic changes." Genes Chromosomes Cancer 2: 
210-216. 
 
Dunaief, J., S. BE, et al. (1994). "The retinoblastoma protein and BRG1 form a complex and 
cooperate to induce cell cycle arrest." Cell 79: 119-130. 
 
Edelman, G. and F. s. Jones (1998). "Gene regulation of cell adhesion: a key step in neural 
morphogenesis." Brain Res Rev 26: 337-352. 
 
Feinberg, A. and B. Tycko (2004). "The history of cancer epigenetics." Nature Reviews 
Cancer 4: 143-153. 
 
 122
Finkelstein, S. D., W. Marsh, et al. (2003). "Microdissection-based allelotyping discriminates 
de novo tumor from intrahepatic spread in hepatocellular carcinoma." Hepatology 
37(4): 871-9. 
 
Foster, S., D. Wong, et al. (1998). "Inactivation of p16 in human mammary epithelial cells by 
CpG island methylation." Mol Cell Biol 18: 1793-1801. 
 
Fraga, M., E. Ballestar, et al. (2005). "Loss of acetylation at Lys16 and trimethylation at 
Lys20 of Histone H4 is a common hallmark of human cancer." Nat Genet 37: 391-400. 
 
Fryer, C. J. and T. K. Archer (1998). "Chromatin remodelling by the glucocorticoid receptor 
requires the BRG1 complex." Nature 393(6680): 88-91. 
 
Fujisawa, H., K. Misaki, et al. (2005). "Cyclin D1 is overexpressed in atypical 
teratoid/rhabdoid tumor with hSNF5/INI1 gene inactivation." Journal of Neuro-
Oncology 73: 117-124. 
 
Fukuoka, J., T. Fujii, et al. (2004). "Chromatin remodeling factors and BRM/BRG1 
expression as prognostic indicators in non-small cell lung cancer." Clin Cancer Res 10: 
4314-24. 
 
Gartel, A. and K. Shchors (2003). "Mechanisms of c-myc mediated transcriptional repression 
of growth arrest genes." Exp Cell Res 283: 17-21. 
 
Glavac, D., M. Volavsek, et al. (2003). "Low microsatellite instability and high loss of 
heterozygosity rates indicate dominant role of the suppressor pathway in squamous cell 
carcinoma of head and neck and loss of heterozygosity of 11q14.3 correlates with 
tumor grade." Cancer Genet Cytogenet 146(1): 27-32. 
 
Goel, A., C. N. Arnold, et al. (2003). "Characterization of sporadic colon cancer by patterns 
of genomic instability." Cancer Res 63(7): 1608-14. 
 
Gonzalex-Crussi, F., R. Goldschmidt, et al. (1982). "Infantile sarcoma with intracytoplasmic 
filamentous inclusions. Distinctive tumor of possible histiocytic origin." Cancer 49: 
2365-75. 
 
Guidi, C. (2001). "Disruption of Ini1 leads to peri-implantation lethality and tumorigenesis in 
mice." Mol Cell Biol 21: 3598-3603. 
 
Guidi, C., R. Mudhasani, et al. (2006). "Functional interaction of the retinoblastoma and 
ini1/snf5 tumor suppressors in cell growth and pituitary tumorigenesis." Cancer Res 66: 
8076-82. 
 
Gunduz, E., M. Gunduz, et al. (2005). "Genetic and Epigenetic alterations of BRG1 promote 
oral cancer development." Int J Oncol 26: 201-10. 
 
 123
Haas, J., N. Palmer, et al. (1981). "Ultrastructure of malignant rhabdoid tumor of he kidney: 
A distinctive renal tumor of children." Hum Pathol 12: 646-57. 
 
Hansen, R. and M. Oren (1997). "p53; from inductive signal to cellular effect." Curr. Opin. 
Genet. Dev 7: 46-51. 
 
Harikrishnan, K. N., M. Z. Chow, et al. (2005). "Brahma links the SWI/SNF chromatin-
remodeling complex with MeCP2-dependent transcriptional silencing." Nat Genet 
 15696166 37(3): 254-64. 
 
Harvey, M., M. J. McArthur, et al. (1993). "Spontaneous and carcinogen-induced 
tumorigenesis in p53-deficient mice." Nat Genet 5(3): 225-9. 
 
Hendricks, K., F. Shanahan, et al. (2004). "Role for BRG1 in cell cycle control and tumor 
suppression." Mol. Cell. Biol. 24: 362-376. 
 
Herzog, C. R., K. A. Crist, et al. (2001). "Chromosome 3p tumor-suppressor gene alterations 
in cervical carcinomas." Mol Carcinog 30(3): 159-68. 
 
Hessman, O., D. Lindberg, et al. (1999). "Genetic alterations on 3p, 11q13, and 18q in 
nonfamilial and MEN 1-associated pancreatic endocrine tumors." Genes Chromosomes 
Cancer 26(3): 258-64. 
 
Hill, D., I. de la Serna, et al. (2004). "BRCA1 interacts with dominant negative SWI/SNF 
enzymes without affecting homologous recombination or radiation induced gene 
activation of p21 or Mdm2." J Cell Biochem 91: 987-98. 
 
Howes, K., N. Ransom, et al. (1994). "Apoptosis or retinoblastoma: alternative fates of 
photoreceptors expressing the HPV-16  E7 gene in the presence or absence of p53." 
Genes and Development 8(1300-10). 
 
Hu, N., M. J. Roth, et al. (2000). "Identification of novel regions of allelic loss from a 
genomewide scan of esophageal squamous-cell carcinoma in a high-risk Chinese 
population." Genes Chromosomes Cancer 27(3): 217-28. 
 
Hudson, B. P., M. A. Martinez-Yamout, et al. (2000). "Solution structure and acetyl-lysine 
binding activity of the GCN5 bromodomain." J Mol Biol 304(3): 355-70. 
 
Hussein, M. R. and G. S. Wood (2002). "Microsatellite instability and its relevance to 
cutaneous tumorigenesis." J Cutan Pathol 29(5): 257-67. 
 
Hussein, M. R. and G. S. Wood (2002). "Molecular aspects of melanocytic dysplastic nevi." 
J Mol Diagn 4(2): 71-80. 
 
Hussein, M. R. and G. S. Wood (2002). "Microsatellite instability in human melanocytic skin 
tumors: an incidental finding or a pathogenetic mechanism?" J Cutan Pathol 29(1): 1-4. 
 124
 
Hussein, M. R. and G. S. Wood (2002). "Building bridges in cancer: mismatch repair and 
microsatellite instability." Am J Dermatopathol 24(1): 76-81. 
 
Iacobuzio-Donahue, C. A., M. S. van der Heijden, et al. (2004). "Large-scale allelotype of 
pancreaticobiliary carcinoma provides quantitative estimates of genome-wide allelic 
loss." Cancer Res 64(3): 871-5. 
 
Iakova, P., S. S. Awad, et al. (2003). "Aging reduces proliferative capacities of liver by 
switching pathways of C/EBPalpha growth arrest." Cell 113(4): 495-506. 
 
Isakoff, M., C. Sansam, et al. (2005). "Inactivation of the Snf5 tumor suppressor stimulates 
cell cycle progression and cooperates with p53 loss in oncogenic transformation." Proc 
Natl Acad Sci U S A. 102(49): 17745-50. 
 
Jacks, T., L. Remington, et al. (1994). "Tumor spectrum analysis in p53-mutant mice." Curr 
Biol 4(1): 1-7. 
 
Jackson-Grusby, L., C. Beard, et al. (2001). "Loss of genomic methylation causes p53-
dependent apoptosis and epigenetic deregulation." Nat. Genet. 27: 31-39. 
 
Jeon, S., M. Kang, et al. (1997). "A new mouse gene, Srg3, related to the SWI3 of 
Saccharomyces cerevisiae, is required for apoptosis induced by glucocorticoids in a 
thymoma cell line." J. Exp. Med. 185: 1827-1836. 
 
Ji, L., J. Minna, et al. (2005). "3p21.3 tumor suppressor cluster: prospects for translational 
applicaitons." Future Oncology 1(1): 79-92. 
 
Jones, P. A. and S. B. Baylin (2007). "The epigenomics of cancer." Cell 
128(4): 683-92. 
 
Kalpana, G. V., S. Marmon, et al. (1994). "Binding and stimulation of HIV-1 integrase by a 
human homolog of yeast transcription factor SNF5." Science 266(5193): 2002-6. 
 
Kang, H., K. Cui, et al. (2004). "BRG1 Controls the Activity of the Retinoblastoma Protein 
via Regulation of p21CIP1/WAF1/SD1." Mol Cell Biol 24(3): 1188-1199. 
 
Killary, A. M., M. E. Wolf, et al. (1992). "Definition of a tumor suppressor locus within 
human chromosome 3p21-p22." Proc Natl Acad Sci U S A 89(22): 10877-81. 
 
Kim, J., S.-o. Huh, et al. (2001). "Srg3, A Mouse Homolog of Yeast SWI3, Is Essential for 
Early Embryogenesis and Involved in Brain Development." Mol Cell Biol 21(22): 
7787-7795. 
 
Kingston, R. (1996). "Repression and activation by multiprotein complexes that alter 
chromatin structure." Genes and Development 10: 905-920. 
 125
 
Kingston, R. and G. Narlikar (1999). "ATP-dependent remodeling and acetylation as 
regulators of chromatin fluidity." Genes and Development 13: 2339-2352. 
 
Kiyono, T., S. Foster, et al. (1998). "Both Rb/p16INK4A inactivation and telomerase activity 
are required to immortalize human epithelial cells." Nature 396: 84-88. 
 
Klochendler-Yeivin, A., L. Fiette, et al. (2000). "The murine SNF5/INI1 chromatin 
remodeling factor is essential for embryonic development and tumor suppression." 
EMBO Reports 1: 500-6. 
 
Klochendler-Yeivin, A., E. Picarsky, et al. (2006). "Increased DNA Damage Sensitivity and 
Apoptosis in Cells Lacking the Snf5/Ini1 Subunit of the SWI/SNF Chromatin 
Remodeling Complex." Mol Cell Biol 26(7): 2661-2674. 
 
Ko, M., J. Jang, et al. (2004). "T Cell Receptor Signalling Inhibits Glucocorticoid-Induced 
Apoptosis by Repressing the SRG3 Expression via Ras Activation." The Journal of 
Biological Chemistry 279: 21903-21915. 
 
Kuroki, T., Y. Tajima, et al. (2005). "Genetic alterations in gallbladder carcinoma." Surg 
Today 35(2): 101-5. 
 
Kuroki, T., F. Trapasso, et al. (2003). "Allele loss and promoter hypermethylation of VHL, 
RAR-beta, RASSF1A, and FHIT tumor suppressor genes on chromosome 3p in 
esophageal squamous cell carcinoma." Cancer Res 63(13): 3724-8. 
 
Laird, P. (2005). "Cancer epigenetics." Hum Mol Genet 14(1): R65-R76. 
 
Laurent, B. C., M. A. Treitel, et al. (1991). "Functional interdependence of the yeast SNF2, 
SNF5, and SNF6 proteins in transcriptional activation." Proc Natl Acad Sci U S A 
88(7): 2687-91. 
 
Lee, C., H. Sohn, et al. (1999). "Interaction of E1 and hSNF5 proteins stimulates replication 
of human papillomavirus DNA." Nature 399: 487-91. 
 
Lee, D., K. JW, et al. (2002). "SWI/SNF complex interacts with tumor suppressor p53 and is 
necessary for the activation of p53-mediated transcription." J Biol. Chem 277: 22330-7. 
 
Lerman, M. I. and J. D. Minna (2000). "The 630-kb lung cancer homozygous deletion region 
on human chromosome 3p21.3: identification and evaluation of the resident candidate 
tumor suppressor genes. The International Lung Cancer Chromosome 3p21.3 Tumor 
Suppressor Gene Consortium." Cancer Res 60(21): 6116-33. 
 
Levine, A. (1997). "p53, the cellular gatekeeper for growth and division." Cell 88: 323-331. 
 
 126
Li, E., T. Bestor, et al. (1992). "Targeted mutation of the DNA methyltransferase gene results 
in embryonic lethality." Cell 69: 915-926. 
 
Li, M., Z. F. Zhang, et al. (1996). "Chromosome 3 allelic losses and microsatellite alterations 
in transitional cell carcinoma of the urinary bladder." Am J Pathol 149(1): 229-35. 
 
Lickert, H., J. K. Takeuchi, et al. (2004). "Baf60c is essential for function of BAF chromatin 
remodelling complexes in heart development." Nature 432(7013): 107-12. 
 
Link, K. A., C. J. Burd, et al. (2005). "BAF57 governs androgen receptor action and 
androgen-dependent proliferation through SWI/SNF." Mol Cell Biol 
 
Liu, R., H. Liu, et al. (2001). "Regulation of CSF1 promotor by the SWI/SNF-like BAF 
complex." Cell 106: 309-18. 
 
Liu, X. Q., H. K. Chen, et al. (2003). "Alterations of BLU, a candidate tumor suppressor 
gene on chromosome 3p21.3, in human nasopharyngeal carcinoma." Int J Cancer 
106(1): 60-5. 
 
Lo, K. W. and D. P. Huang (2002). "Genetic and epigenetic changes in nasopharyngeal 
carcinoma." Semin Cancer Biol 12(6): 451-62. 
 
Lo, K. W., P. M. Teo, et al. (2000). "High resolution allelotype of microdissected primary 
nasopharyngeal carcinoma." Cancer Res 60(13): 3348-53. 
 
Lowe, S., T. Jacks, et al. (1994). "Abrogation of oncogene-associated apoptosis allows 
transformation of p53-deficient cells." Proc Natl Acad Sci U S A 91: 2026-30. 
 
Lu, X., G. Magrane, et al. (2001). "Selective Inactivation of p53 Facilitates Mouse Epithelial 
Tumor Progression without Chromosomal Instability." Mol. Cell. Biol. 21(17): 6017-
6030. 
 
Lund, A. and M. van Lohuizen (2004). "Epigenetics and cancer." Genes and Development 
18: 2315-35. 
 
Lynch, H., S. Shurin, et al. (1983). "Paravertebral malignant rhabdoid tumor in infancey. In 
vitro studies of a familial tumor." Cancer 52: 290-96. 
 
MacDonald, T., B. Rood, et al. (2003). "Advances in the diagnosis, molecular genetics, and 
treatment of pediatric embryonal CNS tumors." Oncologist 8(2): 174-186. 
 
Macleod, K., Y. Hu, et al. (1996). "Loss of Rb activates both p53-dependent and independent 
cell death pathways in the developing mouse nervous system." EMBO  J 15: 6178-
6188. 
 
 127
Maitra, A., Wistuba, II, et al. (2001). "High-resolution chromosome 3p allelotyping of breast 
carcinomas and precursor lesions demonstrates frequent loss of heterozygosity and a 
discontinuous pattern of allele loss." Am J Pathol 159(1): 119-30. 
 
Manderson, E. N., N. Presneau, et al. (2002). "Comparative analysis of loss of heterozygosity 
of specific chromosome 3, 13, 17, and X loci and TP53 mutations in human epithelial 
ovarian cancer." Mol Carcinog 34(2): 78-90. 
 
Medjkane, S., E. Novikov, et al. (2002). "The tumor suppressor hSNF5/INI1 modulates cell 
growth and actin cytoskeleon organization." Cancer Res 64: 3406-13. 
 
Miller, B. J., D. Wang, et al. (2003). "Pooled analysis of loss of heterozygosity in breast 
cancer: a genome scan provides comparative evidence for multiple tumor suppressors 
and identifies novel candidate regions." Am J Hum Genet 73(4): 748-67. 
 
Minna, J. D., K. Fong, et al. (2002). "Molecular pathogenesis of lung cancer and potential 
translational applications." Cancer J 8 Suppl 1: S41-6. 
 
Minna, J. D., J. A. Roth, et al. (2002). "Focus on lung cancer." Cancer Cell 1(1): 49-52. 
 
Mitelman, F., F. Mertens, et al. (1997). "A breakpoint map of recurrent chromosomal 
rearrangements in human neoplasia." Nat Genet 15 Spec No: 417-74. 
 
Morgenbesser, S. D., B. O. Williams, et al. (1994). "p53-dependent apoptosis produced by 
Rb-deficiency in the developing mouse lens." Nature 371(6492): 72-4. 
 
Muchardt, C., C. Sardet, et al. (1996). "A human protein with homology to Saccharomyces 
and cerevisiae SNF5 interacts with the potential helicase hbrm." Nucleic Acids Res 23: 
1127-32. 
 
Mueller, R. F. and N. J. Lench (2000). "Mapping of the DFNB1 locus." Adv 
Otorhinolaryngol 56: 116-23. 
 
Nagl, N. (2005). "The p270 (ARID1A/SMARCF1) Subunit of Mammalian SWI/SNF Related 
Complexes is Essential for normal cell cycle arrest." Cancer Res 65(20): 9236-44. 
 
Nuovo, G., T. Plaia, et al. (1999). "In situ detection of the hypermethyulation-induced 
inactivation of the p16 gene as an early event in oncogenesis." Proc Natl Acad Sci U S 
A 96: 12754-12759. 
 
Okano, M., D. Bell, et al. (1999). "DNA methyltansferases Dnmt3a and Dnmt3b are essential 
for de novo methylation and mammalian development." Cell 99: 247-257. 
 
Oruetxebarria, I., F. Venturini, et al. (2004). "p16INK4a is required for hSNF5 chromatin 
remodeler-induced cellular senescence in malignant rhabdoid tumor cells." J Biol. 
Chem 279: 3807-16. 
 128
 
Pan, H. and A. Griep (1995). "Temporally distinct patterns of p53-dependent and p53-
independent apoptosis during mouse lens development." Genes and Development 9: 
2157-2169. 
 
Pazirandeh, A., Y. Xue, et al. (2002). "Effects of altered glucocorticoid sensitivity in the T 
cell lineage on thymocyte and T cell homeostasis." Faseb J 16(7): 727-9. 
 
Perez-Martin, J. and A. Jonson (1998). "The C-terminal domain of Sin1 interacts with the 
SWI/SNF complex in yeast." Mol. Cell. Biol. 18: 4157-64. 
 
Peterson, C. L. and I. Herskowitz (1992). "Characterization of the yeast SWI1, SWI2, and 
SWI3 genes, which encode a global activator of transcription." Cell 68(3): 573-83. 
 
Pihan, G. (2003). "Mutations and aneuploidy: conspirators in cancer?" Cancer Cell 4(2): 89-
94. 
 
Reddy, A. (2005). "Atypical teratoid/rhabdoid tumors of the central nervous system." J 
Neurooncol. 75(3): 309-313. 
 
Reed, S. I. (1997). "Control of the G1/S transition." Cancer Surv 29: 7-23. 
 
Reisman, D., J. Sciarrotta, et al. (2003). "Loss of BRG1/BRM in human lung cancer cell 
lines and primary lung cancers: correlation with poor prognosis." Cancer Res 63: 560-
566. 
 
Resnitzky, D., M. Gossen, et al. (1994). "Acceleration of the G1/S phase transtion by 
expression of cyclins D1 andE with an inducible system." Mol Cell Biol 14: 1669-
1679. 
 
Reyes, J., J. Barra, et al. (1998). "Altered control of cellular proliferation in the absence of 
mammalian brahma (SNF2alpha)." EMBO  J 17: 6679-6991. 
 
Reynolds, P., M. Sigaroudinia, et al. (2006). "Tumor suppressor p16ink4a regulates 
polycomb-mediated DNA hypermethylation in human mammary epithelial cells." J 
Biol. Chem 281: 24790-24802. 
 
Reznikoff, C. A., C. D. Belair, et al. (1996). "A molecular genetic model of human bladder 
cancer pathogenesis." Semin Oncol 23(5): 571-84. 
 
Riazimand, S. H., H. J. Welkoborsky, et al. (2002). "Investigations for fine mapping of 
amplifications in chromosome 3q26.3-28 frequently occurring in squamous cell 
carcinomas of the head and neck." Oncology 63(4): 385-92. 
 
Riggs, A. and P. Jones (1983). "5-methylcytosine, gene regulation, adn cancer." Adv. Cancer 
Res. 40: 1-30. 
 129
 
Roberts, C., S. Galusha, et al. (2000). "Haploinsufficiency of Snf5 (integrase interactor 1) 
predisposes to malignant rhabdoid tumors in mice." Proc Natl Acad Sci U S A 97: 
13796-13800. 
 
Roberts, C., M. Leroux, et al. (2002). "Highly penetrant, rapid tumorigenesis through 
conditional inversion of the tumor suppressor gene Snf5." Cancer Cell 2: 415-25. 
 
Roberts, C. and S. H. Orkin (2004). "The SWI/SNF Complex- Chromatin and Cancer." 
Nature Reviews Cancer 4: 132-142. 
 
Rocha, S., M. Garrett, et al. (2005). "Regulation of NF-kappaB and p53 through activation of 
ATR and Chk1 by the ARF tumor suppressor." EMBO J 24: 1157-1169. 
 
Rodrigues-Serpa, A., A. Catarino, et al. (2003). "Loss of heterozygosity in follicular and 
papillary thyroid carcinomas." Cancer Genet Cytogenet 141(1): 26-31. 
 
Rorke, L. B., R. J. Packer, et al. (1996). "Central nervous system atypical teratoid/rhabdoid 
tumors of infancy and childhood: definition of an entity." J Neurosurg 85(1): 56-65. 
 
Rosty, C., M. Peter, et al. (1998). "Cytogenetic and molecular ananlysis of a 
t(1;22)(p36;q11.2) in a rhabdoid tumro with a putative homozygous deletion of 
chromosome 22." Genes Chromosomes Cancer 21: 82-89. 
 
Rousseau-Merck, M., I. Versteege, et al. (1999). "hSNF5/INI1 inactivation is mainly 
associatd with homozygous deletions and mitotic recombinations in rhabdoid tumors." 
Cancer Res 59: 3152-56. 
 
Sabbatini, P., J. Lin, et al. (1995). "Essential role for p53-mediated transcription in E1A-
induced apoptosis." Genes and Development  2184-2192. 
 
Seligson, D. B., S. Horvath, et al. (2005). "Global histone modification patterns predict risk 
of prostate cancer recurrence." Nature 435(7046): 1262-6. 
 
Senchenko, V., J. Liu, et al. (2003). "Deletion mapping using quantitative real-time PCR 
identifies two distinct 3p21.3 regions affected in most cervical carcinomas." Oncogene 
22(19): 2984-92. 
 
Seo, S., G. Richardson, et al. (2005). "The SWI/SNF chromatin remodeling protein Brg1 is 
required for vertebrate neurogenesis and mediates transactivation of Ngn and NeuroD." 
Development 132: 105-115. 
 
Sevenet, N., A. Lellouch-Tubiana, et al. (1999a). "Spectrum of hSNF5/INI1 somatic 
mutations in human cancer and genotype-phenotype correlations." Hum Mol Genet 8: 
2359-2368. 
 
 130
Sevenet, N., E. Sheridan, et al. (1999b). "Constitutional mutation of the mutations of the 
hSNF5/INI1 gene predispose to a variety of cancers." Am J Hum Genet 65: 1342-8. 
 
Shanahan, F., W. Seghezzi, et al. (1999). "Cyclin E associates with BAF155 and BRG1, 
components of the mammalian SWI-SNF complex and alters the ability of BRG1 to 
induce growth arrest." Mol Cell Biol 19: 1460-1469. 
 
Sharples, N. (2001). "Loss of p16INK4A with retention of p19Arf predisposes mice ot 
tumorigenesis." Nature 413: 86-91. 
 
Sherr, C. (1996). "Cancer cell cycles." Science 274: 1672-77. 
 
Sherr, C. (2004). "Principles of tumor suppression." Cell 116(2): 235-46. 
 
Sherr, C. and F. McCormick (2002). "The RB and p53 pathways in cancer." Cancer Cell 
2(2): 103-112. 
 
Shimada, Y., F. Sato, et al. (2000). "Loss of fragile histidine triad gene expression is 
associated with progression of esophageal squamous cell carcinoma, but not with the 
patient's prognosis and smoking history." Cancer 89(1): 5-11. 
 
Simone, C. (2006). "SWI/SNF: The Crossroads Where Extracellular Signaling Pathways 
Meet Chromatin." Journal of Cellular Physiology 207: 309-314. 
 
Simone, C., S. Forcales, et al. (2004). "p38 Pathway targets SWI-SNF chromatin-remodeling 
complex to muscle-specific loci." Nat Genet 36: 738-743. 
 
Simsir, A., D. Palacios, et al. (2001). "Detection of loss of heterozygosity at chromosome 
3p25-26 in primary and metastatic ovarian clear-cell carcinoma: utilization of 
microdissection and polymerase chain reaction in archival tissues." Diagn Cytopathol 
24(5): 328-32. 
 
Singh, P., J. Coe, et al. (1995). "A role for retinoblastoma protein in potentiating 
transcriptional activation by the glucocorticoid receptor." Nature 374(6522): 562-5. 
 
Sohn, D., K. Lee, et al. (2007). "SRG3 interacts directly with the major components of the 
SWI/SNF chromatin remodeling complex and protects them form proteasomal 
degradation." JBC in press - eprint: manuscript: M610563200. 
 
Stobeck, M., A. Fribourg, et al. (2000b). "Restoration of retinoblastoma mediated signaling 
to Cdk2 results in cell cycle arrest." Oncogene 19: 1857-1867. 
 
Stobeck, M., E. Knudsen, et al. (2000a). "BRG1 is required for RB-mediated cell cycle 
arrest." Proc Natl Acad Sci U S A 97(7748-7753). 
 
 131
Stobeck, M., D. Reisman, et al. (2002). "Compensation of BRG1 function by Brm: insight 
into the role of the core SWI-SNF subunits in retinoblastoma tumor suppressor 
signaling." Journal of Biological Chemistry 277: 4782-9. 
 
Stober, B., J. Dunaief, et al. (1996). "Functional interactions between the hBRM/hBRG1 
transcriptional activators and the pRB family of proteins." Mol Cell Biol 16(1576-
1583). 
 
Sudarsanam, P., V. R. Iyer, et al. (2000). "Whole-genome expression analysis of snf/swi 
mutants of Saccharomyces cerevisiae." Proc Natl Acad Sci U S A 97(7): 3364-9. 
 
Symonds, H., L. Krall, et al. (1994). "p53-dependent apoptosis suppresses tumor growth and 
progression in vivo." Cell 78: 703-11. 
 
Trouche, D., C. Le Chalony, et al. (1997). "RB and hbrm cooperate to repress the activation 
fuctions of E2F1." Proc Natl Acad Sci U S A 94: 11268-11273. 
 
Tsai, L.-H., E. Lees, et al. (1993). "The cdk2 kinase is required for the G1-to-S transition in 
mammalian cells." Oncogene 8: 1593-1602. 
 
Tsikitis, M., Z. Zhang, et al. (2005). "Genetic ablation of Cyclin D1 abrogates genesis of 
rhabdoid tumors resulting from Ini1 loss." Proc Natl Acad Sci U S A 102(34): 12129-
34. 
 
Tsuneyoshi, M., Y. Daimaru, et al. (1985). "Malignant soft tissue neoplasms with the 
histologic features of renal rhabdoid tumors: An ultrastructural and 
immunohistochemical study." Hum Pathol 16: 1235-42. 
 
Tzai, T. S., H. H. Chen, et al. (2003). "Clinical significance of allelotype profiling for 
urothelial carcinoma." Urology 62(2): 378-84. 
 
Uno, F., J. Sasaki, et al. (2004). "Myristoylation of the fus1 protein is required for tumor 
suppression in human lung cancer cells." Cancer Res 64(9): 2969-2676. 
 
Vacchio, M. S., J. Y. Lee, et al. (1999). "Thymus-derived glucocorticoids set the thresholds 
for thymocyte selection by inhibiting TCR-mediated thymocyte activation." J Immunol 
163(3): 1327-33. 
 
van den Heuvel, S. and E. Harlow (1993). "Distinct roles for cyclin-dependent kinases in cell 
cycle control." Science 262(2050-2054). 
 
Velickovic, M., B. Delahunt, et al. (2001). "VHL and FHIT locus loss of heterozygosity is 
common in all renal cancer morphotypes but differs in pattern and prognostic 
significance." Cancer Res 61(12): 4815-9. 
 
 132
Versteege, I., S. Medjkane, et al. (2002). "A key role of the hSNF5/INI1 tumour suppressor 
in the controll of the G1-S transition of the cell cycle." Oncogene 21: 6403-12. 
 
Versteege, I., J. Sevenet, et al. (1998). "Truncating mutations of hSNF5/INI1 in aggressive 
paediatric cancer." Nature 394: 201-206. 
 
Vogelstein, B., D. Lane, et al. (2000). "Surfing the p53 network." Nature 408: 307-310. 
 
Vousden, K. (2000). "p53: death star." Cell 103: 691-694. 
 
Vousden, K. and X. Lu (2002). "Live or Let Die: the cell's response to p53." Nature Reviews 
Cancer 2: 594-604. 
 
Vries, R. G. J., V. Bezrookove, et al. (2006). "Cancer-associated mutations in chromatin 
remodeler hSNF5 promote chromosomal instability by compromising the mitotic 
checkpoint." Genes and Development 19: 665-670. 
 
Wagner, A., J. Kokontis, et al. (1994). "Myc-mediated apoptosis requires wild-type p53 in a 
manner independent of cell cycle arrest and the ability of p53 to induce p21 waf1/cip1." 
Genes and Development 8: 2817-30. 
 
Wang, T., C. Rago, et al. (2002). "Prevalence of somatic alterations in the colorectal cancer 
cell genome." Proc Natl Acad Sci U S A 99(5): 3076-80. 
 
Wang, W. (2003). "The SWI/SNF family of ATP-dependent chromatin remodelers: similar 
mechanisms for diverse functions." Curr. Top. Microbiol. Immunol. 274: 143-169. 
 
Wang, W., J. Cote, et al. (1996). "Purification and biochemical heterogeneity of the 
mammalian SWI-SNF complex." Embo J 15(19): 5370-82. 
 
Wang, W., Y. Xue, et al. (1996b). "Diversity and specialization of mammalian SWI/SNF 
complexes." Genes and Development 10(2117-2130). 
 
Wang, Z., J. Cummins, et al. (2004). "Three classes of genes mutated in colorectal cancers 
with chromosomal instability." Cancer Res 64(4): 2998-3001. 
 
Wang, Z., W. Zhai, et al. (2004). "Polybromo protein BAF180 functions in mammalian 
cardia chamber maturation." Genes and Development 18: 3106-3116. 
 
Wei, F., J. Ni, et al. (2002). "Cytogenetic studies of esophageal squamous cell carcinomas in 
the northern Chinese population by comparative genomic hybridization." Cancer Genet 
Cytogenet 138(1): 38-43. 
 
Weinberg, A. (1995). "The retinoblastoma protein and cell cycle control." Cell 81: 323-30. 
 
 133
Winston, F. and M. Carlson (1992). "Yeast SNF/SWI transcriptonal activators and the 
SPT/SIN chromatin connection." Trends Genet 8: 387-91. 
 
Wistuba, II, A. Maitra, et al. (2002). "High resolution chromosome 3p, 8p, 9q and 22q 
allelotyping analysis in the pathogenesis of gallbladder carcinoma." Br J Cancer 87(4): 
432-40. 
 
Wistuba, II, M. Tang, et al. (2001). "Genome-wide allelotyping analysis reveals multiple 
sites of allelic loss in gallbladder carcinoma." Cancer Res 61(9): 3795-800. 
 
Wong, A., F. Shanahan, et al. (2000). "BRG1, a component of the SWI/SNF complex, is 
mutated in multiple human tumor cell lines." Cancer Res 60: 6171-6177. 
 
Wu, D., D. Tkachunk, et al. (2002). "The human SNF5/INI1 protein facilitates the function 
of the growth arrest and DNA damage inducible protein (GADD34) and modulates 
GADD34-bound protein phosphatase-1 activity." J Biol. Chem 277: 27706-27715. 
 
Xiang, H., D. Hockman, et al. (1996). "Evidence for p53-mediated modulation of neuronal 
viability." J. Neurosci 16: 6753-65. 
 
Yan, Z., K. Cui, et al. (2005). "PBAF chromatin-remodeling complex requires a novel 
specificity subunit, BAF200, to regulate expression of selective interferon-responsive 
genes." Genes and Development 19: 1662-1667. 
 
Yang, Q., G. Yoshimura, et al. (2002). "Chromosome 3p and breast cancer." J Hum Genet 
47(9): 453-9. 
 
Yashiro, M., J. M. Carethers, et al. (2001). "Genetic pathways in the evolution of 
morphologically distinct colorectal neoplasms." Cancer Res 61(6): 2676-83. 
 
Zabarovski, E., M. Lerman, et al. (2002). "Tumor Suppressor genes on chromosome 3p 
involved in the pathogenesis of lung and other cancers." Oncogene 21: 6915-6935. 
 
Zhang, H., M. Gavin, et al. (2000). "Exit from G1 and S phase of the cell cycle is regulated 
by repressor complexes containing HDAC-Rb-hSWI/SNF and Rb-hSWI/SNF." Cell 
101: 19-89. 
 
Zhang, Y., H. Ng, et al. (1999). "Analysis of the NuRD subunits reveals a histone 
deacetylase core complex and a connection with DNA methylation." Genes and 
Development 13: 1924-35. 
 
Zhang, Z., K. Davies, et al. (2002). "Cell cycle arrest and repression of cyclin D1 
transcription by INI1/SNF5." Mol Cell Biol 22: 5975-88. 
 
 134
Zraly, C., D. Marenda, et al. (2004). "SNR1 (INI1/SNF) mediates important cell grwoth 
functions of the Drosophila Brahama (SWI/SNF) chromatin remodeling complex." 
Genetics 168: 199-214. 
 
 
 
 
 
 
 135
